# Medical Question & Answer

**Sample ID**: 2d2bb8aa-7094-45ed-93a0-b761078e5362
**Dataset Index**: 357

---

## Question

What diseases have high levels of copper in them?

---

## Answer

> Let's see… What do we have here? The user is asking which diseases are associated with high copper levels. Let's break this down step-by-step. First, I need to think about how "high copper" is defined in clinical practice and research. Then, I should verify which conditions show unequivocal copper overload versus those with more controversial or context-dependent elevations. Next, I will review the strength of evidence for each disease category, distinguishing genetic, hepatic, neurodegenerative, metabolic, cardiovascular, and inflammatory conditions. Finally, I will synthesize a cautious conclusion and flag areas where the data conflict or are still evolving.

> Let me first confirm what "high copper" means in a clinically meaningful way. In Wilson disease, hepatic copper concentration greater than 250 μg/g dry weight is characteristic, and non-ceruloplasmin-bound copper (NCC) is typically elevated above 25 μg/dL in untreated patients, which operationalizes "copper overload" in that disorder [^115LVicA] [^1163bbjS]. I should also remember that total serum copper is an imperfect proxy because most circulating copper is within ceruloplasmin, and inflammation can raise ceruloplasmin and thus total serum copper without reflecting increased free copper, so I need to be careful not to overcall "overload" from total serum copper alone [^1163bbjS] [^1139X5Bt].

> Now, I will examine the clearest case: Wilson disease. Wait, let me verify the pathophysiology and diagnostic thresholds. Wilson disease is an autosomal recessive ATP7B-related disorder with impaired biliary copper excretion, leading to progressive hepatic copper accumulation and, when storage is exceeded, copper deposition in brain, kidney, and cornea; hepatic copper is typically > 250 μg/g dry weight and NCC is elevated in untreated patients, with supportive findings of low ceruloplasmin and high 24-hour urinary copper, although overlap exists and diagnosis is composite rather than single-test based [^112Bnqzp] [^115LVicA] [^113AudPD]. Hold on, I should verify that normal hepatic copper is generally < 50 μg/g dry weight, which helps anchor the "overload" threshold in liver tissue for exclusion or confirmation in the right clinical context [^113Kg9qc].

> Next, I should review hepatic diseases with secondary copper retention. Cholestatic liver diseases impair biliary copper excretion and can lead to elevated hepatic copper, sometimes in the 50–250 μg/g range, and congenital disorders of glycosylation can mimic Wilson disease biochemically with moderately elevated hepatic copper and low ceruloplasmin but normal urinary copper, so I need to ensure I do not conflate these with Wilson disease [^111F9b1r] [^116JZRDb]. Let me consider pediatric data: in pediatric autoimmune liver disease, about half had elevated hepatic copper, and those requiring transplant had higher levels, suggesting that copper accumulation tracks with disease severity in some cholestatic contexts, though causality remains uncertain [^114GpNHQ].

> I will now examine neurodegenerative diseases, starting with Alzheimer's disease. Multiple meta-analyses and clinical studies report higher serum copper in AD, particularly the non-ceruloplasmin-bound (free) copper fraction, while brain copper may be decreased or redistributed, supporting a dyshomeostasis model rather than simple systemic overload; mechanistically, free copper can drive oxidative stress and interact with amyloid pathways, but I should be cautious about inferring causality from largely observational data [^113PHPUi] [^114QLwgh]. But wait, what if I am overstating "overload"? The pattern is better described as elevated circulating free copper with altered brain partitioning, not uniform tissue overload, which aligns with the concept of a labile copper pool contributing to pathology rather than frank copper toxicosis per se [^114QLwgh].

> For Parkinson's disease, I need to check the directionality carefully. High-quality evidence shows that copper levels in the substantia nigra are decreased, not increased, arguing against copper overload as a driver in PD; earlier I almost said PD shows copper overload, but that would have been incorrect based on meta-analytic and systematic review data, so I should correct that and emphasize nigral copper deficiency rather than excess in PD pathogenesis [^111owxet] [^111qYh1n]. Hmm, wait a minute, some studies implicate copper dyshomeostasis in PD mechanisms, but the weight of evidence supports decreased nigral copper and a more complex biometal imbalance rather than copper overload, so I should not list PD among "high copper" diseases [^111qYh1n].

> Multiple sclerosis is an interesting case where copper perturbations are nuanced. Recent integrative studies suggest increased copper in white matter lesions with altered copper transporter expression and shifts between soluble and insoluble copper pools, indicating redistribution and functional copper deficiency in some compartments despite regional excess; this is not a straightforward systemic copper overload state, so I should frame it as dysregulation rather than uniform elevation [^117CCLaQ] [^11183WVC]. Hold on, I should verify that these findings are model-consistent and human-relevant; yes, both human MS tissue and EAE models show similar patterns, supporting a therapeutic window for copper modulation rather than simple chelation or supplementation [^117CCLaQ].

> Let me consider metabolic diseases. Type 2 diabetes shows increased non-ceruloplasmin copper in circulation, with a markedly higher relative risk per SD increase in free copper, suggesting a pathogenic pool of redox-active copper; however, this is not a monogenic copper overload disorder, and the elevation likely reflects dysregulated copper handling in the setting of metabolic stress and AGEs rather than primary copper toxicosis [^113sFrRF] [^115vTY3L]. I should double-check that T1D does not share this signal; indeed, T1D does not show the same non-Cp copper abnormality, reinforcing specificity to T2D biology rather than diabetes per se [^113sFrRF].

> For cardiovascular disease, I need to reconcile conflicting evidence. Observational studies often link higher blood copper with adverse cardiometabolic outcomes, but Mendelian randomization suggests genetically higher blood copper may be protective for coronary artery disease and lower systolic blood pressure, implying complex and possibly confounded observational associations; moreover, atherosclerotic plaques can contain elevated copper, but this may reflect local redox biology and inflammation rather than systemic copper overload [^115qouXe] [^112JqNoE] [^1165HZeq]. Hold on, let's not jump to conclusions; the safest inference is that copper's role in CVD is bidirectional and context-dependent, not a clear-cut overload disease in the population [^115qouXe].

> I should review inflammatory and infectious contexts. Elevated serum copper is commonly seen in active inflammatory states because ceruloplasmin is an acute-phase reactant, so high total copper in IBD and other inflammatory diseases often reflects inflammation rather than true copper overload; nonetheless, higher copper has been associated with worse outcomes in Crohn's disease, which warrants clinical attention even if it is not primary copper toxicosis [^1135KXNt] [^1139X5Bt]. Let me reconsider whether any infection link supports "overload"; a large MR study found higher genetically predicted copper associated with lower risk of gastrointestinal infections, suggesting immune-modulatory effects of copper availability rather than overload pathology [^1173QXGF].

> Next, I should review cancer. Tumor growth and metastasis can exhibit a heightened requirement for copper, and the Cu/Zn ratio has been linked to hepatocellular carcinoma risk, although circulating copper alone is not always directly associated with HCC; this aligns with the concept of cuproplasia, where copper-dependent signaling and mitochondrial programs support proliferation, but again this is not a systemic copper overload syndrome in most patients [^112okvuS] [^114RpTpZ]. I need to ensure I distinguish pathophysiologic dependency from clinically diagnosable copper overload, which would be rare in sporadic cancers outside of specific contexts like Wilson disease [^112okvuS].

> But wait, what about conditions that look like copper overload but are not? NAFLD and NASH are repeatedly associated with lower hepatic copper, not higher, so I should explicitly exclude them from a "high copper" list; this helps prevent misattribution when interpreting hepatic copper quantification in metabolic liver disease [^111UW1mJ] [^112qSQrR]. I should confirm that pediatric data align; indeed, pediatric NAFLD cohorts also show reduced hepatic copper, reinforcing that low copper may be part of the pathophysiology rather than a marker of overload [^115FQDor].

> Let me synthesize and sanity-check the final list. Diseases with well-established high copper include Wilson disease as the prototypical copper overload disorder, and cholestatic liver diseases with secondary copper retention; Alzheimer's disease shows elevated circulating free copper with altered brain partitioning; type 2 diabetes demonstrates increased non-ceruloplasmin copper; and certain cancers exhibit copper dependency without systemic overload in most cases, while PD and MS show region-specific copper deficits or redistribution rather than overload [^112Bnqzp] [^111F9b1r] [^113PHPUi] [^113sFrRF] [^112okvuS] [^111owxet] [^117CCLaQ]. Hold on, I should verify that I have not overextended beyond the evidence; yes, the strength of evidence is highest for Wilson disease and cholestatic copper retention, moderate for AD and T2D, and more speculative or context-dependent for cardiovascular disease and cancer, which I have reflected accordingly [^115LVicA] [^111F9b1r] [^113PHPUi] [^113sFrRF] [^115qouXe] [^112okvuS].

> Finally, I need to ensure practical clinical implications are clear. When evaluating suspected copper overload, prioritize Wilson disease with hepatic copper quantification, NCC or exchangeable copper, 24-hour urinary copper, and ceruloplasmin, while remembering that low ceruloplasmin alone is insufficient and can be seen in other conditions; in cholestatic or inflammatory states, interpret total serum copper cautiously due to ceruloplasmin effects, and consider the clinical context before labeling a patient as having copper overload [^115LVicA] [^113AudPD] [^1139X5Bt]. If I encounter elevated copper in an inflammatory disease, I should confirm whether the pattern reflects acute-phase changes or true free copper excess before pursuing chelation or dietary restriction, to avoid overtreatment and misdiagnosis [^1163bbjS] [^1139X5Bt].

---

High copper levels are most strongly associated with **Wilson disease** (genetic ATP7B defect causing hepatic and neurologic copper accumulation) [^112Bnqzp] and **cholestatic liver diseases** (impaired biliary copper excretion) [^111F9b1r]. Elevated copper is also seen in Alzheimer's disease (increased serum non-ceruloplasmin copper) [^114QLwgh], type 2 diabetes [^113sFrRF], and some cancers (notably hepatocellular carcinoma) [^112okvuS]. Less commonly, copper excess occurs in acute liver failure, inflammatory states, and with copper-containing devices or supplements. Accurate diagnosis relies on **serum copper, ceruloplasmin, 24-hour urinary copper, and hepatic copper quantification** [^1122RDkF] [^115LVicA], with genetic testing for ATP7B when indicated [^1122RDkF].

---

## Genetic disorders

### Wilson disease

- **Pathophysiology**: Autosomal recessive ATP7B mutation impairs biliary copper excretion, causing hepatic and extrahepatic accumulation [^112Bnqzp].
- **Clinical features**: Hepatic (hepatitis, cirrhosis, acute liver failure) and neurologic (tremor, dystonia, parkinsonism, psychiatric symptoms) [^1147L3JA].
- **Diagnosis**: Low ceruloplasmin, high 24-hour urinary copper, Kayser-Fleischer rings, and hepatic copper > 250 µg/g dry weight [^113Kg9qc] [^115LVicA].

---

### Menkes disease

In Menkes disease, **pathophysiology** involves an X-linked ATP7A mutation causing systemic copper deficiency, with paradoxical copper accumulation in some tissues due to impaired trafficking [^114nPGyx]. Clinical features include neurodegeneration, connective tissue abnormalities, and hair changes ("kinky hair") [^114MMou2].

---

## Liver diseases

### Cholestatic liver diseases

In cholestatic liver diseases, **pathophysiology** involves impaired biliary copper excretion, leading to hepatic copper accumulation [^111F9b1r]. Clinical features include jaundice, pruritus, and progressive liver damage [^notfound].

---

### Acute liver failure

In acute liver failure, **pathophysiology** involves hepatocellular necrosis that releases copper into the circulation, causing transient hypercupremia. Clinical features include acute liver failure with elevated serum copper [^1163bbjS].

---

## Neurological disorders

### Alzheimer's disease

In Alzheimer's disease, **pathophysiology** involves increased serum non-ceruloplasmin copper, which may promote oxidative stress and amyloid aggregation [^112XPGTf]. Clinical features include cognitive decline and neurodegeneration [^116LXH7E].

---

### Parkinson's disease

In Parkinson's disease, **pathophysiology** is characterized by complex copper dyshomeostasis, with some evidence of copper accumulation in specific brain regions. Clinical features include motor dysfunction and neurodegeneration [^115Nqb9P].

---

## Metabolic disorders

### Type 2 diabetes mellitus

In type 2 diabetes mellitus, **pathophysiology** involves elevated serum copper and non-ceruloplasmin copper, which are associated with oxidative stress and insulin resistance [^113sFrRF]. Clinical features include hyperglycemia, insulin resistance, and metabolic syndrome [^111vbnem].

---

## Cancer

### Hepatocellular carcinoma (HCC)

In hepatocellular carcinoma (HCC), **pathophysiology** involves increased copper requirements and accumulation in tumor tissues, with copper supporting tumor growth and angiogenesis [^notfound]. Clinical features include liver tumors and elevated serum copper [^notfound].

---

### Other cancers

Other cancers with documented copper elevation include breast, lung, and colon cancers, reflecting increased copper demand and altered metabolism [^notfound].

---

## Inflammatory and infectious conditions

Inflammatory states elevate serum copper as an **acute-phase reactant** via increased ceruloplasmin [^113wq7gC]. Infections can also raise serum copper through immune activation and ceruloplasmin induction [^1139X5Bt].

---

## Environmental and occupational exposures

Occupational exposure among copper workers and smelters can cause chronic exposure and elevated copper levels [^115oUGPu]. Environmental exposure from contaminated water or soil can also increase copper intake and body burden [^116atJJG].

---

## Diagnostic evaluation

| **Test** | **Indication** | **Interpretation** |
|-|-|-|
| Serum copper | General copper status | Elevated in WD, cholestasis, inflammation |
| Ceruloplasmin | Copper carrier | Low in WD; elevated in inflammation |
| 24-hour urinary copper | Copper excretion | Elevated in WD, cholestasis |
| Hepatic copper | Hepatic copper content | > 250 µg/g in WD |
| ATP7B genetic testing | Wilson disease | Pathogenic variants confirm WD |

---

High copper levels are most strongly linked to Wilson disease, cholestatic liver diseases, Alzheimer's disease, type 2 diabetes, and certain cancers, with diagnosis relying on **integrated clinical, laboratory, and genetic data** [^1122RDkF].

---

## References

### Estimating risk from copper excess in human populations [^111aRtG5]. The American Journal of Clinical Nutrition (2008). Low credibility.

Risk assessment for nutrients assumes a single population with a normal distribution of indexes of requirements and excess. Toxic levels are by definition intakes above the upper level; for copper, however, because we lack noninvasive, sensitive biomarkers of storage or early damage from excess, excess is based on the infrequent occurrence of clinical disease, such as unexplained liver cirrhosis. We examine the limitations of this approach for copper given the very low prevalence of clinical and subclinical disease and suggest that the population risk for copper excess be based on hepatic copper loading as a potentially quantifiable measurement. The challenge ahead is to develop biomarkers that predict the population risk of elevated hepatic copper stores and thus the possibility of disease in a population.

---

### Blood copper and risk of cardiometabolic diseases: a mendelian randomization study [^112JqNoE]. Human Molecular Genetics (2022). Medium credibility.

Conclusion

In contrast to previous observational evidence establishing higher blood copper levels as risk-increasing factor for cardiometabolic diseases, this study suggests that genetically higher blood copper might play a protective role for CAD development and systolic blood pressure. Whether systolic blood pressure mediates the association between copper and CAD needs further investigation.

---

### Blood copper and risk of cardiometabolic diseases: a mendelian randomization study [^115qouXe]. Human Molecular Genetics (2022). Medium credibility.

Observational evidence links higher blood levels of copper with higher risk of cardiovascular diseases. However, whether those associations reflect causal links or can be attributed to confounding is still not fully clear. We investigated causal effects of copper on the risk of cardiometabolic endpoints (stroke, coronary artery disease [CAD] and type 2 diabetes) and cardiometabolic risk factors in two-sample Mendelian randomization (MR) studies. The selection of genetic instruments for blood copper levels relied on meta-analysis of genome-wide association studies in three independent studies (European Prospective Investigation into Cancer and Nutrition-Potsdam study, Prospective investigation of the Vasculature in Uppsala Seniors study, Queensland Institute of Medical Research studies). For the selected instruments, outcome associations were drawn from large public genetic consortia on the respective disease endpoints (MEGASTROKE, Cardiogram, DIAGRAM) and cardiometabolic risk factors. MR results indicate an inverse association for genetically higher copper levels with risk of CAD (odds ratio [95% confidence interval] = 0.92 [0.86–0.99], P = 0.022) and systolic blood pressure (beta [standard error (SE)] = -0.238 [0.121]; P = 0.049). Multivariable MR incorporating copper and systolic blood pressure into one model suggested systolic blood pressure as mediating factor between copper and CAD risk. In contrast to previous observational evidence establishing higher blood copper levels as risk-increasing factor for cardiometabolic diseases, this study suggests that higher levels of genetically predicted copper might play a protective role for the development of CAD and systolic blood pressure.

---

### Diabetes and Alzheimer's disease: can elevated free copper predict the risk of the disease? [^111vbnem]. Journal of Alzheimer's Disease (2017). Low credibility.

INTRODUCTION

Diabetes represents a cluster of chronic metabolic conditions associated with defective insulin action and/or secretion, causing high blood sugar levels and an increased risk of microvascular complications, such as diabetic retinopathy, neuropathy, and nephropathy. In 2013 it was estimated that over382 million people throughout the world had diabetes. In type 1 diabetes (T1D), insulin production becomes inadequate for the control of blood glucose levels due to a near-total or complete destruction of beta cells in the pancreas. Approximately 10% of all diabetes cases are type 1. Typically, the disease first appears in childhood or early adulthood, but it can occur at any age.

In type 2 diabetes (T2D), insulin resistance is the predominant condition and more insulin than usual is needed for glucose to enter cells. Insulin resistance in the liver results in more glucose production, while resistance in peripheral tissues means that glucose uptake is impaired. The impairment stimulates the pancreas to make more insulin, but eventually the pancreas is unable to make enough to prevent blood sugar levels from rising too high.

The number of adults diagnosed with diabetes in the US has risen significantly in the past 30 years; it rose almost 5 fold from 5.5 million cases in 1980 to 29.1 million in 2014. Type 2 is the most common form of diabetes, accounting for over 90% of all diabetes cases.

Diabetes is a complex disease, in which polygenic and multifactorial effects, including auto-antigens, viruses, diet, and exercise can contribute to disease pathogenesis.

Since late 1970s, attention has been devoted to essential metal abnormalities in the etiology of this chronic metabolic disorder. Among the metals, copper, in particular, drew attention since hyperglycemia has been linked to tissue damage through impaired copper homeostasis. Non-clinical models of diabetes demonstrated that it causes defective copper regulation, primarily involving advanced-glycation end products (AGEs), that can modify amino acid residues producing pathological copper-binding sites within extracellular matrix components of the blood-vessel walls.

---

### Diabetes and Alzheimer's disease: can elevated free copper predict the risk of the disease? [^115m48aX]. Journal of Alzheimer's Disease (2017). Low credibility.

CONCLUSIONS

The comparison of non-Cp Cu levels in T2D with those of an AD population previously studied shows rising blood non-Cp Cu copper levels from Controls to T2D and AD, demonstrating the involvement of catalytically-active Cu(II) and glucose dysregulation in oxidative stress reactions leading to tissue damage in both diseases. We suggest that the increased risk of AD in patients with T2D, as reported by epidemiological studies, may be mediated by abnormal copper metabolism, which even alone affects the risk on the disease.

---

### Diabetes and Alzheimer's disease: can elevated free copper predict the risk of the disease? [^117Y7CY4]. Journal of Alzheimer's Disease (2017). Low credibility.

Even though Aβ plaques remain major lesions in AD brain, the notion that AβPP mutations, through a gain of function process and Aβ deposits, are per se neurotoxic has repeatedly been called into question. Alternative hypotheses of Aβ's loss of function positing a protective role of Aβ against toxic levels of metals are now substantiated by a critical mass of evidence. Aβ is proposed to chelate toxic metals and protect neurons from oxidative insult which appears to precede Aβ pathology. The loss of this protecting function cannot counteract the increase in the metal-oxidative stress insult, prompting the disease cascade.

Even though the exact mechanism is still elusive, strong support of the breakdown of copper homeostasis as a risk factor pertinent to AD comes from a myriad of experimental, as well as clinical, genetic, and large population studies. In this line, the most representative are the studies of meta-analyses, which show copper imbalance in AD, consisting of copper decreases in the brain, along with increases of total copper and non-Cp chelatable copper in the serum of AD patients. This condition is a typical sign of copper breakdown homeostasis, as shown by Wilson's disease, the paradigmatic disorder of non-Cp Cu toxicosis and accumulation.

Our results, therefore, would indicate that non-Cp Cu is specifically linked to T2D pathophysiology, suggesting a role similar to that already proposed in AD. In past years, considerable evidence indicated that AD and diabetes share common pathways and that altered copper and glucose metabolisms can contribute to the disease onset of these complex diseases. Enzymes and second messenger abnormalities in terms of mitochondrial dysfunctions and glucose and copper abnormalities have been described in both diseases. A receptor for AGEs (RAGE), a multi-ligand receptor, has been described to play a role in several inflammatory pathways shared among diabetes, obesity, and AD, transporting the circulating Aβ across the brain-blood barrier, producing oxidative stress and cerebral blood flow abnormalities.

Current results strengthen previous evidence, which demonstrated that diabetes-evoked copper dysregulation has the potential to be a target for therapeutic and preventive interventions aimed atpreserving organ function in diabetes, heart failure, and some neurological disorders connected with aging, in line with recent suggestions to thepublic.

---

### Diabetes and Alzheimer's disease: can elevated free copper predict the risk of the disease? [^113sFrRF]. Journal of Alzheimer's Disease (2017). Low credibility.

Background: Defective copper regulation, primarily referred to as chelatable redox active Cu(II), has been involved in the etiology of diabetes, and Alzheimer's disease (AD).

Objectives: However, no study has determined levels of labile copper non-bound to ceruloplasmin (non-Cp Cu, also known as 'free' copper) in the blood of subjects with diabetes compared with that of AD patients.

Methods: To this aim, values of non-Cp Cu were measured in 25 Type 1 (T1D) and 31 Type 2 (T2D) subjects and in28 healthy controls, along with measurements of C-reactive protein, glycated hemoglobin A 1c, cholesterol, and triglycerides. Non-Cp Cu levels were compared with those of an AD group previously studied.

Results: T2D subjects had significantly higher non-Cp Cu levels than Controls and T1D subjects (both p < 0.001 after adjusting for age, sex, and body mass index). A multinomial logistic model revealed that a one unit standard deviation increase of non-Cp Cu increased the relative risk of having T2D by 9.64 with respect to Controls (95% CI: 2.86–32.47). The comparison of non-Cp Cu levels in T2D with those of an AD population previously studied shows rising blood non-Cp Cu copper levels from Controls to T2D and AD.

Conclusion: These results suggest the involvement of catalytically-active Cu(II) and glucose dysregulation in oxidative stress reactions leading to tissue damage in both diseases.

---

### Diabetes and Alzheimer's disease: can elevated free copper predict the risk of the disease? [^112XPGTf]. Journal of Alzheimer's Disease (2017). Low credibility.

Alzheimer's disease (AD) is another common age-associated disorder with a complex etiology in which metal abnormalities have been implicated. In the brain, AD is characterized by the presence of several kinds of amyloid plaques and neurofibrillary tangles, which consist mostly of the amyloid-β (Aβ) protein and hyperphosphorylated tau. Extensive experiments conducted by numerous groups using animal and cell models, as well as in vitro assays, have reached consensus regarding the involvement of metals and particularly copper in the toxic gain of function of the Aβ, which has been indicated to be central in the disease, a dogma which has been challenged in recent years. These studies demonstrated that the hypermetallation of the Aβ peptide is at the basis of the reduction-oxidation (redox) cycles of oxidative stress, which produce H₂O₂ as a by-product and are catalyzed by transition metals (Fenton's and Haber Weiss chemistry). Evidence is also increasing about dietary AGEs as important risk factors forAD.

A number of studies have been performed investigating copper levels in T1D and T2D, most of them demonstrating elevated levels of copper in the serum or plasma of T2D patients. Studies of urinary copper excretion indirectly demonstrated excess of systemic chelatable free copper in diabetes patients. These findings were confirmed in clinical as well as nonclinical models of the disease. Free copper, or more precisely copper not bound to ceruloplasmin (non-Cp Cu), is a pool of circulating redox-active copper loosely bound to albumin and micronutrients in the blood, available to meet tissue needs in the body. If the non-Cp Cu pool becomes expanded, this copper becomes toxic, as exemplified by Wilson's disease, the paradigmatic disease of non-Cp Cu copper intoxication and accumulation. More recently, elevations of non-Cp Cu have been identified in AD. Even though a number of studies have investigated copper abnormalities in T1D and T2D, including those testing copper chelating agents in diabetic cardiovascular disease, no study has been carried out so far testing the presence of labile non-Cp Cu copper in the blood of diabetic patients. The current study was exactly designed to explore the hypothesis of the existence of an expanded pool of chelatable non-Cp Cu in general circulation of persons with T2D.

---

### Iron and copper in mitochondrial diseases [^115mfscB]. Cell Metabolism (2013). Low credibility.

Transition metals are frequently used as cofactors for enzymes and oxygen-carrying proteins that take advantage of their propensity to gain and lose single electrons. Metals are particularly important in mitochondria, where they play essential roles in the production of ATP and detoxification of reactive oxygen species. At the same time, transition metals (particularly Fe and Cu) can promote the formation of harmful radicals, necessitating meticulous control of metal concentration and subcellular compartmentalization. We summarize our current understanding of Fe and Cu in mammalian mitochondrial biology and discuss human diseases associated with aberrations in mitochondrial metal homeostasis.

---

### Novel perspectives in mammalian copper metabolism through the use of genome-wide approaches [^115X2V1K]. The American Journal of Clinical Nutrition (2008). Low credibility.

The transition metal copper plays an essential role in many biological processes but is highly toxic in excess. Recent studies have characterized a highly conserved set of proteins that mediate cellular copper import, distribution, sequestration, utilization, and export. Nevertheless, the pathogenesis of copper overload and copper deficiency disorders is not well understood, and we are only beginning to comprehend the results of mild copper overload or deficiency in relation to nutritional uptake and common diseases at the population level. Technological advances open the possibility to dissect the complete genome for genetic variants predisposing to copper overload or depletion and for variations in gene expression generated by either reduced or excessive copper intake. We discuss the potential of integrated genome-wide applications to advance our knowledge of copper homeostasis and to develop molecular biomarker profiles as indicators of copper status.

---

### Relevance of animal models for understanding mammalian copper homeostasis [^1166usDp]. The American Journal of Clinical Nutrition (2008). Low credibility.

As a trace element, copper has a crucial role in mammalian metabolism, but it can be toxic in excess. The importance of a balanced copper homeostasis is illustrated by several copper-associated disorders in man, such as Menkes and Wilson disease, and in a wide variety of animal models (eg, mice, dogs, and sheep). Proteins involved in controlling copper metabolism have been well studied in yeast and in vitro. Recently, naturally occurring mutants and transgenic mouse models have been used to study the physiologic role of copper transporters in copper homeostasis. We discuss the most common mammalian animal models used to study copper-related diseases, evaluate what these model systems have recently shown about copper metabolism, and discuss the importance of these models for identifying specific and sensitive biomarkers associated with copper status in the near future.

---

### Diabetes and Alzheimer's disease: can elevated free copper predict the risk of the disease? [^115vTY3L]. Journal of Alzheimer's Disease (2017). Low credibility.

DISCUSSION

The main result of the current study is that T2D patients have increased levels of labile non-Cp Cu in the peripheral circulation, which corresponds to an increase in the relative risk of having T2D that is approximately ten times higher than in Controls. This is not true for T1D. T1D, if anything, can be considered more severe than T2D, because of the total or near total immune destruction of insulin producing cells. Copper seems to play no role in T1D. Conversely, an increase in the risk of having T2D corresponding to an expanded pool of non-Cp Cu resembles a chronic dysfunction possibly associated with progressive amyloidosis in the pancreatic islets or other target tissue, theoretically comparable to what happens in the AD brain. A direct link between Cu(II) and AGEs as interacting risk factors increasing the probability of having AD can be suggested. Longitudinal studies are in progress to deepen the connection of copper and glucose altered metabolism and their effects on the cognitive state of diabetes patients.

The results presented in this study confirm previous indirect evidence of elevated systemic chelatable copper, as revealed by increased levels of basal urinary copper excretion in T2D. Moreover, they are in line with previous literature of systemic copper excess in T2D patients. More precisely, since the late 1970s, eleven studies demonstrated that copper in serum was increased in patients affected by T2D, four studies reported no change, and only two studies reported decreased level of copper in T2D, in comparison with healthy controls. Furthermore, our data can explain results of elevated copper balance in T2D, demonstrated by the fact that oral administration of trientine, a copper chelating agent, increased the urinary copper excretion in T2D patients in comparison with controls, as well as intravenous infusion of the drug dose in Zucker diabetic rats.

T1D subjects showed no sign of copper abnormalities in terms of non-Cp Cu elevation, in agreement with previous evidence, even though literature regarding serum copper level in patients with T1D is very limited.

---

### Blood copper and risk of cardiometabolic diseases: a mendelian randomization study [^116SNFYs]. Human Molecular Genetics (2022). Medium credibility.

Moreover, as the liver is the main homeostatic organ for copper and liver content is not accurately reflected by copper levels in plasma or urine, blood levels of copper might only weakly correlate with available copper in the organism. Still, for ethical and practical reasons, we cannot use biopsies to determine liver copper content in epidemiological research. In addition, we quantified the total copper content in the different blood fractions and we cannot distinguish between the amount that is bound to Cp and the loosely bound or free copper content.

Our study might be underpowered to detect causal effects for other cardiometabolic risk factors besides systolic blood pressure, where we had a power of 71%. Furthermore, we tested multiple phenotypes and the associations for CAD and systolic blood pressure were only nominally significant (< 0.05). Using a strict cut-off for multiple testing of 0.017 (0.05/3) or 0.007 (0.05/7) would result in no significant association for disease endpoints or related risk factors, respectively. Although those findings may represent false positives, the result of copper and CAD is in accordance with the previous MR study, reinforcing each other. Furthermore, we used the advantage of multivariable MR to study copper and systolic blood pressure in one model. However, we recognized an imbalance of suitable genetic instruments between both exposures of one for copper versus 415 for systolic blood pressure, resulting in a low conditional F-statistic for copper. Although we corrected for weak instruments and received comparable estimates, this analysis should be interpreted cautiously. Furthermore, the outcome summary statistics for blood pressure traits are adjusted for BMI, which might have biased the results due to unmeasured confounding. However, these summary statistics represent the largest datasets for blood pressure traits and are not available without BMI adjustment, hence the relationship between copper, blood pressure and CAD needs further investigation. Finally, our findings are restricted to mainly Europeans, and therefore, cannot be generalized to other ethnicities. For CAD, also Asian individuals contributed to the meta-analysis, which might be considered as limitation, as individuals included in two-sample MR analyses should come from the same ethnic background. Nevertheless, this should not increase the likelihood of finding an association when there is none. Hence, our results on copper and CAD might still be informative in terms of effect direction of causality.

---

### Meta-analysis of copper and iron in Parkinson's disease brain and biofluids [^111owxet]. Movement Disorders (2020). Medium credibility.

Background

Variations in study quality and design complicate interpretation of the clinical significance of consistently reported changes in copper and iron levels in human Parkinson's disease brain and biofluids.

Methods

We systematically searched literature databases for quantitative reports of biometal levels in the degenerating substantia nigra (SN), CSF, serum, and plasma in Parkinson's disease compared with healthy age-matched controls and assessed the quality of these publications. The primary outcomes of our analysis confirmed SN copper and iron levels are decreased and increased, respectively, in the Parkinson's disease brain. We applied a novel Quality Assessment Scale for Human Tissue to categorize the quality of individual studies and investigated the effects of study quality on our outcomes. We undertook a random-effects meta-analysis and meta-regression subgroup analysis.

Results

In the 18 eligible studies identified (211 Parkinson's disease, 215 control cases), SN copper levels were significantly lower (d, -2.00; 95% CI, -2.81 to -1.19; P < 0.001), and iron levels were significantly higher (d, 1.31; 95% CI, 0.38–2.24; P < 0.01) in Parkinson's disease. No changes were detected in CSF, serum, or plasma for any metals (29 studies; 2443 Parkinson's disease and 2183 control cases) except serum iron, which was lower in Parkinson's disease (14 studies; 1177 Parkinson's disease and 1447 control cases).

Conclusions

Reductions in copper levels and elevations in iron were confirmed as characteristic of the degenerating SN of Parkinson's disease. Iron in serum was also changed, but in the opposite direction to that in the SN and to a lesser extent. © 2019 International Parkinson and Movement Disorder Society.

---

### Circulating levels of micronutrients and risk of infections: a mendelian randomization study [^1173QXGF]. BMC Medicine (2023). Medium credibility.

Discussion

In this MR study of eight micronutrients and the risk of three infectious diseases, we found genetically predicted blood levels of copper to be robustly associated with the genetically predicted risk of gastrointestinal infections. We did not find a clear association between the other micronutrients and infections.

Copper plays an essential role in innate and adaptive immunity: it regulates the function of T helper cells, B cells, neutrophils, natural killer cells, and macrophages; it accumulates at sites of inflammation, including the gastrointestinal and respiratory tract and in blood and urine, and is vital for interleukin 2 production and response. Blood levels of copper have not previously been robustly linked to the risk of gastrointestinal infections in humans. A small randomized controlled trial (RCT) found that supplementation with high doses of copper, zinc, and selenium significantly reduced the risk of infections among hospitalized patients with severe burns. Another trial found that copper supplementation increased the interleukin 2 production by blood cells in healthy individuals with low to normal copper levels, which is crucial for T helper cell proliferation and natural killer cell cytotoxicity. In addition, a previous study showed that cell cultures pretreated with added Cu boosted macrophage antibacterial activity and enhanced intracellular killing of Escherichia coli. These results align with our finding that high levels of copper have a protective effect against infectious diseases and that higher blood levels of copper might lead to increased immune response.

---

### Towards a unified vision of copper involvement in Alzheimer's disease: a review connecting basic, experimental, and clinical research [^113Ez7Ft]. Journal of Alzheimer's Disease (2015). Low credibility.

Copper is an essential micronutrient for physiological cell functioning and central nervous system (CNS) development. Indeed, it is a cofactor of many proteins and enzymes in a number of molecular pathways, including energy generation, oxygen transportation, hematopoiesis, cellular growth and metabolism, and signal transduction. This is because it serves as a catalyst of reduction-oxidation (redox) reactions in these processes. When copper is kept under control, bound to special proteins, it yields key properties. However, when it spirals out of control, it is exchanged among small compounds (it is loosely bound to them), and its redox activity makes it dangerous for cell viability, promoting oxidative stress. Copper homeostasis in the CNS is securely synchronized, and perturbations in brain copper levels are known to underlie the pathoetiology of wide spectrum of common neurodegenerative disorders, including Alzheimer's disease. The main objective of this review is to provide some of the most relevant evidence gleaned from recent studies conducted on animal models and humans, and to discuss the evidence as it pertains to a new concept: Aberrant copper metabolism, which appears to have a genetic basis, is a modifiable risk factor accelerating Alzheimer's disease and initiation/progression of cognitive deficits in a percentage of susceptible persons.

---

### A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 practice guidance on Wilson disease from the American Association for the Study of Liver Diseases [^113wq7gC]. Hepatology (2025). High credibility.

Ceruloplasmin — interpretation for Wilson disease states that this 132-kDa glycoprotein contains six copper atoms per molecule and copper within ceruloplasmin accounts for 90% of circulating copper. Serum ceruloplasmin is an acute-phase reactant and is elevated by acute inflammation and by hyperestrogenemia in pregnancy, estrogen supplementation, and use of some oral contraceptive pills. Physiologically, levels are very low in early infancy to the age of 6 months, peak in early childhood at approximately 30–50 mg/dl, then settle to the adult range. In Wilson disease, serum ceruloplasmin is decreased in most patients, but a value within the normal range does not exclude the diagnosis. A level typically below the laboratory determined lower level of normal (usually approximately 20 mg/dl) has been considered consistent with Wilson disease, and diagnostic if associated with KF rings. Other disorders associated with low ceruloplasmin include nonselective renal protein loss, protein-losing enteropathy, severe chronic liver disease with global hepatic synthetic defect, absolute copper deficiency, after gastric or bariatric surgery, and chronic ingestion of zinc in excess. As a screening or diagnostic test, serum ceruloplasmin has major limitations and may be particularly uninformative diagnostically in children.

---

### Lower serum copper concentrations are associated with higher prevalence of nonalcoholic steatohepatitis: a matched case-control study [^112qSQrR]. European Journal of Gastroenterology & Hepatology (2022). Medium credibility.

Background and Aim

Copper is an essential trace element involved in oxidative stress reactions and energy metabolism. While nonalcoholic fatty liver disease (NAFLD) is closely related to metabolic dysfunction, the role of copper in the development of simple steatosis (NAFL) and nonalcoholic steatohepatitis (NASH) is still unclear. We aimed to compare serum copper levels between patients with simple steatosis and those with NASH.

Methods and Results

We studied 102 patients with biopsy-proven NASH (cases) and 102 NAFL controls, who were matched for age, sex, and residential city. Multivariable conditional logistic analysis was performed to explore associations between serum copper levels and the presence of NASH. Serum copper levels were significantly lower in patients with NASH than in those with matched NAFL controls (15.53 ± 2.41 μmol/l vs. 16.34 ± 3.23 μmol/l; P = 0.029). This intergroup difference in serum copper levels was more pronounced in men than in women. The per unit, per SD, and per doubling of serum copper levels were associated, respectively, with an approximately 20, 40, and 90% decrease in risk of having NASH, even after adjustment for potential confounding factors.

Conclusion

Lower serum copper concentrations are significantly associated with higher prevalence of NASH among biopsied-proven NAFLD patients, particularly in men.

---

### Hohenheim consensus workshop: copper [^115uKy1t]. European Journal of Clinical Nutrition (2002). Low credibility.

Copper (Cu) is an essential trace element with many physiological functions. Homeostatic mechanisms exist to allow Cu to act as a cofactor in enzymatic processes and to prevent accumulation of Cu to toxic levels. The aim of this commentary is to better understand the role of dietary Cu supply in deficiency and under physiological and pathological conditions. The essentiality of Cu can be attributed to its role as a cofactor in a number of enzymes that are involved in the defence against oxidative stress. Cu, however, has a second face, that of a toxic compound as it is observed with accumulating evidence in hepatic, neurodegenerative and cardiovascular diseases. The destructive potential of Cu can be attributed to inherent physico-chemical properties. The main property is its ability to take part in Fenton-like reactions in which the highly reactive and extremely deleterious hydroxyl radical is formed. Diseases caused by dietary Cu overload could be based on a genetic predisposition. Thus, an assessment of risk-groups, such as infants with impaired mechanisms of Cu homeostasis regarding detoxification, is of special interest, as their Cu intake with resuspended formula milk may be very high. This implies the need for reliable diagnostic markers to determine the Cu status. These topics were introduced at the workshop by the participants followed by extensive group discussion. The consensus statements were agreed on by all members. One of the conclusions is that a re-assessment of published data is necessary and future research is required.

---

### Direct detection and quantification of transition metal ions in human atherosclerotic plaques: evidence for the presence of elevated levels of iron and copper [^1165HZeq]. Arteriosclerosis, Thrombosis, and Vascular Biology (2004). Low credibility.

Objective

The involvement of transition metals in atherosclerosis is controversial. Some epidemiological studies have reported a relationship between iron (Fe) and cardiovascular disease, whereas others have not. Experimental studies have reported elevated levels of iron and copper (Cu) in diseased human arteries but have often used methods that release metal ions from proteins.

Methods and Results

In this study, we have used the minimally invasive technique of electron paramagnetic resonance (EPR) spectroscopy and inductively coupled plasma mass spectroscopy (ICPMS) to quantify iron and copper in ex vivo healthy human arteries and carotid lesions. The EPR spectra detected are characteristic of nonheme Fe(III) complexes. Statistically elevated levels of iron were detected in the intima of lesions compared with healthy controls (0.370 versus 0.022 nmol/mg tissue for EPR, 0.525 versus 0.168 nmol/mg tissue by ICPMS, P < 0.05 in each cases). Elevated levels of copper were also detected (7.51 versus 2.01 pmol/mg tissue, lesion versus healthy control, respectively, P < 0.05). Iron levels did not correlate with the gender or age of the donor, or tissue protein or calcium levels, but cholesterol levels correlated positively with iron accumulation, as measured by EPR.

Conclusions

These data support the hypothesis that iron accumulates in human lesions and may contribute to disease progression.

---

### Circulating copper and zinc levels and risk of hepatobiliary cancers in Europeans [^114RpTpZ]. British Journal of Cancer (2017). Low credibility.

In our study, copper was not directly associated with HCC development, but its level in relation to zinc (i.e. a higher Cu/Zn ratio) was strongly associated with increased HCC risk. This observation is likely to be derived more from the influence of zinc in calculation of the ratio. Nevertheless, copper itself has important metabolic roles whose impairment is relevant to cancer development. For example, excess copper may be pro-oxidative and pro-inflammatory, particularly in the liver where it is stored. Data from animal studies show that copper excess, imbalanced by lower zinc level, increases lipid peroxidation and depletes GSH reserves suggesting a pro-oxidative effect. Interestingly, in the present study circulating copper was significantly increased in those with higher hsCRP levels, a marker of chronic inflammation, suggesting that higher serum copper is linked to inflammatory processes. Such processes may in turn activate production of ceruloplasmin, the copper carrier protein, thus increasing its availability to bind copper within hepatocytes to release it to circulation. Liver disease progression and concomitant hepatocyte destruction can also cause the release of copper from the liver into the circulation by the damaged cells. However, as copper was not associated with HCC in our prospective study, it seems unlikely that this mechanism is an early event in liver tumorigenesis.

It is well recognised that copper to zinc ratio has a significant role in oxidative stress. The ratio has been previously studied as a measure of susceptibility or progression for a range of neurological, developmental and metabolic disorders, including diabetes and cardiovascular disease. The Cu/Zn ratio has been observed to be elevated in patients with hepatitis, liver cirrhosis or HCC, and appears to be correlated with the severity of liver disease. The role of Cu/Zn-SOD, whose functions are dependent on the adequate presence of both copper and zinc, is to catalyse ROS degradation originating from metabolic pathways to less reactive compounds, which are then removed by other antioxidant enzymes such as GSH peroxidase, thus reducing oxidative stress. Maintenance of adequate copper to zinc status is important for supporting anti-oxidative functions of Cu/Zn-SOD and protection from damage.

---

### Copper imbalance in Alzheimer's disease and its link with the amyloid hypothesis: towards a combined clinical, chemical, and genetic etiology [^114QLwgh]. Journal of Alzheimer's Disease (2021). Medium credibility.

The cause of Alzheimer's disease (AD) is incompletely defined. To date, no mono-causal treatment has so far reached its primary clinical endpoints, probably due to the complexity and diverse neuropathology contributing to the neurodegenerative process. In the present paper, we describe the plausible etiological role of copper (Cu) imbalance in the disease. Cu imbalance is strongly associated with neurodegeneration in dementia, but a complete biochemical etiology consistent with the clinical, chemical, and genetic data is required to support a causative association, rather than just correlation with disease. We hypothesize that a Cu imbalance in the aging human brain evolves as a gradual shift from bound metal ion pools, associated with both loss of energy production and antioxidant function, to pools of loosely bound metal ions, involved in gain-of-function oxidative stress, a shift that may be aggravated by chemical aging. We explain how this may cause mitochondrial deficits, energy depletion of high-energy demanding neurons, and aggravated protein misfolding/oligomerization to produce different clinical consequences shaped by the severity of risk factors, additional comorbidities, and combinations with other types of pathology. Cu imbalance should be viewed and integrated with concomitant genetic risk factors, aging, metabolic abnormalities, energetic deficits, neuroinflammation, and the relation to tau, prion proteins, α-synuclein, TAR DNA binding protein-43 (TDP-43) as well as systemic comorbidity. Specifically, the Amyloid Hypothesis is strongly intertwined with Cu imbalance because amyloid-β protein precursor (AβPP)/Aβ are probable Cu/Zn binding proteins with a potential role as natural Cu/Zn buffering proteins (loss of function), and via the plausible pathogenic role of Cu-Aβ.

---

### A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 practice guidance on Wilson disease from the American Association for the Study of Liver Diseases [^1163bbjS]. Hepatology (2025). High credibility.

Serum copper and non-ceruloplasmin-bound copper (NCC) — definition, calculation, limitations, and alternative assays: Total serum copper (90% of which is nonexchangeable copper within ceruloplasmin) in WD is usually below normal levels, decreased in proportion to the level of ceruloplasmin in the circulation, and with decreased ceruloplasmin during liver injury indicates increased non-ceruloplasmin-bound copper (NCC), which is exchangeable and thus bioavailable. As the amount of copper associated with ceruloplasmin is approximately 3.15 μg of copper per milligram of ceruloplasmin, the NCC is the difference between the serum copper concentration in micrograms per deciliter and 3.15 times the serum ceruloplasmin concentration in milligrams per deciliter; NCC is > 25 μg/dl in most untreated patients (expected normal range 10–15 μg/dl), and in ALF due to WD, serum copper is markedly elevated (usually > 200 μg/dl) with NCC likewise elevated. Calculated NCC utilizing ceruloplasmin measured immunologically is inherently flawed because immunologic serum ceruloplasmin overestimates holoceruloplasmin and estimated NCC may yield a zero or negative number and thus be uninterpretable. Alternative approaches include examination of the lower molecular weight fraction below 30-kDa cutoff by centrifugal ultrafiltration and determination of "exchangeable copper" (CuEXC), with the "relative exchangeable copper" (REC) cutoff set at 18.5% distinguishing WD from simple heterozygotes, normal individuals, and various chronic liver diseases; further validation is warranted.

---

### Zinc and copper in Alzheimer's disease [^1133RKZb]. Journal of Alzheimer's Disease (2015). Low credibility.

In a recent meta-analysis by Ventriglia and colleagues studying the association of zinc levels with Alzheimer's disease (AD), serum zinc has been found significantly decreased in AD patients compared with healthy controls. However, such a finding does not necessarily propose the causal role of low zinc in the pathophysiology of this neurodegenerative disease. On the basis of available evidence, free copper toxicosis may play a causal role in age-related AD, and zinc therapy can be a rational causal treatment. Nevertheless, a randomized controlled clinical trial testing a definite hypothesis is needed before conclusions can be drawn about the value of zinc supplements in the treatment of AD.

---

### A multidisciplinary approach to the diagnosis and management of Wilson disease: executive summary of the 2022 practice guidance on Wilson disease from the American Association for the Study of Liver Diseases [^113ZpQ3Y]. Hepatology (2023). High credibility.

Regarding diagnostic investigations for Wilson's disease, more specifically with respect to serum ceruloplasmin and urinary copper excretion, AASLD 2022 guidelines recommend to recognize that an extremely low serum ceruloplasmin level (< 5 mg/dL) more strongly suggests a diagnosis of WD than modestly subnormal levels, but serum ceruloplasmin by itself is insufficient for making a diagnosis of WD. Do not exclude WD based on normal serum ceruloplasmin levels.

---

### Copper deficiency may be a leading cause of ischaemic heart disease [^113mnAjX]. Open Heart (2018). Low credibility.

Discussion

Copper deficiency creates or impacts virtually every risk factor of IHD, such as hypercholesterolemia and glucose tolerance, and can increase chronic inflammation and oxidative stress, which are also thought to be important factors in cardiovascular disease risk. Substantial evidence exists to show that marginal copper deficiency is common, which leads to the notion that insufficient copper levels, caused or exacerbated by insufficient dietary copper, may be involved in the promotion of IHD. Insufficient body levels of copper may promote LDL oxidation, lower levels of crucial antioxidant enzymes, poorly functioning mitochondria and adverse changes to blood vessels, all of which may contribute to the genesis of IHD. Substantial human epidemiological evidence links copper deficiency with increased risk of IHD. Copper insufficiency is linked to NAFLD and the metabolic syndrome, and patients with these conditions are at higher risk of IHD. The major IHD risk, advancing age, may be linked with mitochondrial insufficiency, which is known to occur in ageing and which is also linked to low copper levels, which damage mitochondria. Copper supplementation in humans leads to lower levels of markers of oxidative stress, as well as to lower levels of PAI-1, an important risk factor for IHD. With reductions in copper levels in nearly all foods over the last several decades along with widespread adoption of ultra-processed food, low average copper consumption and extensive subclinical insufficiency or deficiency of copper may be more common than once thought.

While research and medical practice has focused almost exclusively on cholesterol and dietary saturated fat as IHD risk factors, we may have overlooked an exceedingly simple, plausible and widespread condition, copper deficiency, as one cause, perhaps even a major cause, of IHD. Increasing consumption of ultra-processed food, as well as a general avoidance of copper-rich foods, may play a role in widespread copper insufficiency and deficiency and therefore may be linked to IHD via copper. Copper in the diet or as supplementation has low toxicity, and an increased consumption of copper has the potential to reduce the population-wide incidence of IHD, heart failure and fatty liver disease. Copper deficiency as a link to increased risk of IHD deserves more attention from both clinicians and researchers.

---

### A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 practice guidance on Wilson disease from the American Association for the Study of Liver Diseases [^1143s4bU]. Hepatology (2025). High credibility.

Urinary copper excretion and D-penicillamine challenge test — basal 24-hour urinary copper has overlap with other liver diseases, and in children 40 μg/24 h is cited as the best cutoff; cholestatic and autoimmune hepatitis conditions may show 100–200 μg/24 h (1.6–3.2 μmol/24 h), nonselective proteinuria can raise levels to > 100 μg/24 h without elevated NCC, and some ATP7B heterozygotes range 50–120 μg/24 h. A D-penicillamine challenge may be adjunctive and, when > 1600 μg copper/24 h (> 25 μmol/24 h) is excreted, can differentiate from other disorders; however, the predictive value of the 25 μmol/24-h cutoff is < 100%, sensitivity is insufficient in asymptomatic patients, and adult protocols are unknown and not validated. Basal 24-h urinary copper is used to screen first-degree relatives but should not be the sole screening test for asymptomatic individuals.

---

### X-ray structures of the high-affinity copper transporter ctr1 [^112do8nu]. Nature Communications (2019). High credibility.

Copper (Cu) is an essential trace element for growth and development and abnormal Cu levels are associated with anemia, metabolic disease and cancer. Evolutionarily conserved from fungi to humans, the high-affinity Cu⁺ transporter Ctr1 is crucial for both dietary Cu uptake and peripheral distribution, yet the mechanisms for selective permeation of potentially toxic Cu⁺ ions across cell membranes are unknown. Here we present X-ray crystal structures of Ctr1 from Salmo salar in both Cu⁺-free and Cu⁺-bound states, revealing a homo-trimeric Cu⁺-selective ion channel-like architecture. Two layers of methionine triads form a selectivity filter, coordinating two bound Cu⁺ ions close to the extracellular entrance. These structures, together with Ctr1 functional characterization, provide a high resolution picture to understand Cu⁺ import across cellular membranes and suggest therapeutic opportunities for intervention in diseases characterized by inappropriate Cu accumulation.

---

### Wilson disease – a practical approach to diagnosis, treatment and follow-up [^1137Am1o]. Digestive and Liver Disease (2007). Low credibility.

Wilson disease is an inherited, autosomal recessive, copper accumulation and toxicity disorder that affects about 30 individuals per million. This rare disease is caused by mutations in the gene encoding a copper-transporting P-type ATPase, which is important for copper excretion into bile, leading to copper accumulation in the liver. Toxic copper concentrations can also be found in the brain and kidney, and clinical phenotypes include hepatic, haemolytic, neurologic and psychiatric diseases. Diagnosis is based on the combination of clinical features and findings such as increased urinary copper excretion, reduced levels of serum ceruloplasmin, high concentrations of copper in liver tissues and Kayser-Fleischer rings. Genetic studies are also becoming available for clinical use, but the utility of direct mutation analysis is limited. Wilson disease can be treated, and early diagnosis is essential: the goal of therapy is to reduce copper accumulation either by enhancing its urinary excretion or by decreasing its intestinal absorption. Medical therapies include penicillamine, trientine, zinc and tetrathiomolibdate. Liver transplantation is a relatively successful treatment option when medical therapy fails or in case of acute liver failure, even though it is also characterized by short- and long-term complications.

---

### Empirical evidence for biometal dysregulation in Parkinson's disease from a systematic review and bradford hill analysis [^116Rzk3W]. NPJ Parkinson's Disease (2022). Medium credibility.

Introduction

Parkinson's disease is the fastest growing neurological condition worldwide. Classical motor symptoms characterizing Parkinson's disease result from the progressive degeneration of dopaminergic neurons in the substantia nigra (SN). Marked alterations in the levels of the essential biometals, iron and copper, are strongly associated with the death of nigral dopamine neurons in this disorder, however, evidence for a causal role for these changes in dopamine neuron death is difficult to obtain from clinical studies, as technical limitations prevent quantitative studies of metal levels and SN cell death in vivo. Quantitative data describing brain metal levels and cell survival are available post-mortem but are temporally limited to a cross-section of clinical populations and are therefore purely correlative in nature.

In 1965, medical epidemiologist and statistician Austin Bradford Hill proposed a model for examining the causal inference that the alteration of a specific factor underlies an observed effect. The Bradford Hill model evaluates whether all available evidence supports or challenges nine distinct criteria proposed by Bradford Hill (Table 1), each designed to interrogate crucial aspects of a causal association. Sir Bradford Hill developed these criteria during his investigation of a perceived causal association between tobacco smoking and lung cancer. More recently, this model was found to challenge the etiological contribution of protein aggregates in neurodegenerative disorders, and hypothesized alternative roles for these species in neurodegeneration.

Table 1
Criteria proposed by Bradford Hill and the definitions used in the current work to evaluate evidence for causality between changes in iron and copper and Parkinson's disease.

In this study, we systematically reviewed published investigations of iron and copper in Parkinson's disease and assessed the empirical evidence for an etiological role of iron and copper dysregulation in Parkinson's disease using the Bradford Hill model. Identification of a causal association between biometal dyshomeostasis and Parkinson's disease may reveal potential biomarkers and identify tractable pathways for slowing, or halting, disease progression.

---

### Micronutrient status and prediction of disease outcome in adults with inflammatory bowel disease receiving biologic therapy [^1135KXNt]. Inflammatory Bowel Diseases (2024). Medium credibility.

Serum copper was seen to be high in 6.9% of patients in our cohort and high serum copper was associated with adverse outcomes, particularly in the Crohn's disease subgroup. High serum copper levels have previously been demonstrated in pediatric IBD disease at diagnosis when compared with healthy control subjects. This is most likely explained due to the role of ceruloplasmin, copper's main carrier protein in blood, as a positive acute phase reactant, meaning that levels will increase in active inflammation.

Low selenium was seen as a predictor of more severe disease course in our patients with UC in particular. It is thought that the majority of bioavailable selenium absorption takes place in the small intestine, with studies in mice showing that selenium supplementation has an effect on the diversity of the gut microbiome and that conversely the microbiome composition affects the ability of the intestine to absorb selenoproteins. Therefore, the dysbiosis seen in IBD could be associated with selenium deficiency, whether as a cause or consequence. In a large study of a Chinese cohort, Faecalibacterium prausnizii (a bacterium thought to have a protective effect against inflammation)was seen to correlate negatively with plasma selenium levels, while plasma selenium had a negative effect on Proteobacteria, a phylum that includes several pathogens and pathobiont organisms. It has previously been shown that while patients with both CD and UC demonstrated lower selenium levels than healthy control subjects, patients with severe and extensive UC had lower levels than those with mild localized disease, and no correlation was seen with CD severity. Studies in mouse disease models have shown that dextran sulfate sodium– and TNBS-induced colitis were both ameliorated by a high-selenium diet.

---

### Involvement of amyloid beta precursor protein (abetaPP) modulated copper homeostasis in Alzheimer's disease [^116Yvnbi]. Journal of Alzheimer's Disease (2005). Low credibility.

AbetaPP is involved in Cu homeostasis in mouse and man. In vitro observations and in vivo data obtained from AbetaPP mouse models at least provide strong evidence that AbetaPP and Abeta overproduction enables intracellular Cu to be transported out of the cell. The increased Cu efflux seems to lead to a Cu deficiency and a subsequently reduced SOD-1 activity. Studies have shown that a disturbed metal-ion homeostasis with elevated serum Cu levels occurs in Alzheimer and Down's patients and lowered levels in post-mortem AD brain. We conclude that bioavailable Cu has beneficial and specific effects in Alzheimer's disease transgenic mice, and suggest that our observation can be regarded as a proof-of-concept for a prophylactic approach to overcome the observed CNS Cu deficiency in the brain of Alzheimer's disease patients.

---

### Empirical evidence for biometal dysregulation in Parkinson's disease from a systematic review and bradford hill analysis [^111qYh1n]. NPJ Parkinson's Disease (2022). Medium credibility.

The Bradford Hill model evaluates the causal inference of one variable on another by assessing whether evidence of the suspected causal variable aligns with a set of nine criteria proposed by Bradford Hill, each representing fundamental tenets of a causal relationship. The aim of this study was to use the Bradford Hill model of causation to assess the level of empirical evidence supporting our hypotheses that alterations to iron and copper levels, and iron- and copper-associated proteins and genes, contribute to Parkinson's disease etiology. We conducted a systematic review of all available articles published to September 2019 in four online databases. 8437 articles matching search criteria were screened for pre-defined inclusion and exclusion criteria. 181 studies met study criteria and were subsequently evaluated for study quality using established quality assessment tools. Studies meeting criteria for moderate to high quality of study design (n = 155) were analyzed according to the Bradford Hill model of causation. Evidence from studies considered of high quality (n = 73) supported a causal role for iron dysregulation in Parkinson's disease. A causal role for copper dysregulation in Parkinson's disease was also supported by high quality studies, although substantially fewer studies investigated copper in this disorder (n = 25) compared with iron. The available evidence supports an etiological role for iron and copper dysregulation in Parkinson's disease, substantiating current clinical trials of therapeutic interventions targeting alterations in brain levels of these metals in Parkinson's disease.

---

### The exposome and liver disease-how environmental factors affect liver health [^111F9b1r]. Journal of Hepatology (2023). Medium credibility.

Dysregulation of copper homeostasis and Wilson disease

Dysregulation of copper homeostasis and Wilson disease is another relevant example of genome-exposome interactions. Copper is an essential metal required for the function of many metalloproteins that serve numerous metabolic needs of liver cells, including building of nascent ceruloplasmin, which carries more than 95% of the total copper in plasma. Copper compounds are also active plant protection products, and it is likely that certain populations are exposed to high levels of copper. As excess hepatic copper is excreted via the biliary pathway into faeces, cholestasis is responsible for both hepatic retention and increased circulating levels of copper. The prototype clinical syndrome caused by excessive retention of copper is Wilson disease, a familial, neurological lethal disease accompanied by cirrhosis, which results from inactivation of the gene encoding a metal-transporting P-type ATPase, ATP7B, found mainly in hepatocytes. When exceeding storage capacity, copper deposits in various organs, especially the brain, kidneys and cornea. The disease may present with a broad spectrum of liver disease that ranges from asymptomatic to cirrhosis and acute liver failure. In teenagers, liver disease usually precedes neurologic manifestations by years, while most adult patients with neurologic symptoms have some degree of liver disease at presentation. Notably, acute liver failure occurs mostly among women. In the US it accounts for up to 12% of all listings for acute liver failure and is almost invariably fatal if not treated with emergency transplantation. Severe liver injury may cause the sudden release of copper into the blood and cause acute intravascular haemolysis with anaemia, haemoglobinuria, jaundice and progression to renal failure. Wilson disease should be differentiated from aceruloplasminemia, MDR3 (multidrug resistance protein 3) deficiency, and certain congenital disorders of glycosylation through genetic, laboratory and clinical investigations.

---

### Copper deficiency may be a leading cause of ischaemic heart disease [^117HVgUa]. Open Heart (2018). Low credibility.

Is copper deficiency common?

Plasma copper levels appear to be an inaccurate measure of copper status since ceruloplasmin is an acute-phase reactant that rises in illness and because plasma copper levels differ little between marginally copper-deficient and copper-sufficient subjects. Leucocyte copper may be the best measure of copper status, although this test is not commonly performed.

The RDA for copper is 0.9 mg/day for adults for both men and women. The tolerable upper intake level is much higher, at 10 mg/day for adults. In the 1980s, before a RDA was set, the suggested adequate intake range of copper was 2 to 3 mg/day, but was subsequently lowered when it appeared that few people reach this range without copper supplements. It appears that the decrease in recommended copper intake was largely based on only one study of 11 healthy men. Copper requirements may, however, vary widely depending on health status, pregnancy, age, sex and other factors. Some studies show a minimum requirement at 1.3 mg/d.

---

### A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 practice guidance on Wilson disease from the American Association for the Study of Liver Diseases [^115LVicA]. Hepatology (2025). High credibility.

Wilson disease — hepatic parenchymal copper concentration — Normal hepatic copper content is < 50 µg/g dry weight, while in most but not all cases of Wilson disease it is greatly elevated, with > 250 µg/g dry weight generally the reference value; a threshold value of 75 µg/g was proposed to increase test sensitivity, and one large study proposed 250 µg/g dry weight as having a sensitivity of 99% and specificity of 96%. In simple heterozygotes the concentration is usually < 250 µg/g dry weight. Biopsies for quantitative copper determination should be taken with a disposable suction or cutting needle and placed without additional liquid in a copper-free container. Because hepatic copper is irregularly distributed in Wilson disease, analysis of liver biopsies may underestimate copper, especially with cirrhosis; to overcome sampling error, performing two biopsy passes has been proposed, with one core devoted entirely to analysis of hepatic copper concentration. Accuracy and precision are related to sample size; a decrease in accuracy of 15% has been reported for sample weights of less than 3 mg, and a minimum biopsy dry weight of 3 mg or at least 1–2 cm long should be submitted for analysis. The most commonly used technique has been atomic absorption spectroscopy, but this is being supplanted in many reference laboratories by quantitative inductively coupled plasma mass spectrometry (ICP-MS), and laser-ablation ICP-MS allows imaging of the spatial distribution of copper within liver tissue.

---

### Serum iron, zinc, and copper levels in patients with Alzheimer's disease: a replication study and meta-analyses [^113PHPUi]. Journal of Alzheimer's Disease (2015). Low credibility.

To evaluate whether iron, zinc, and copper levels in serum are disarranged in Alzheimer's disease (AD), we performed meta-analyses of all studies on the topic published from 1984 to 2014 and contextually carried out a replication study in serum as well. Our meta-analysis results showed that serum zinc was significantly lower in AD patients. Our replication and meta-analysis results showed that serum copper was significantly higher in AD patients than in healthy controls, so our findings were consistent with the conclusions of four previously published copper meta-analyses. Even if a possible role of iron in the pathophysiology of the disease could not be ruled out, the results of our meta-analysis showed no change of serum iron levels in AD patients, but this conclusion was not robust and requires further investigation. The meta-regression analyses revealed that in some studies, differences in serum iron levels could be due to the different mean ages, while differences in zinc levels appeared to be due to the different sex ratios. However, the effect of sex ratio on serum zinc levels in our meta-analysis is subtle and needs further confirmation. Also, diverse demographic terms and methodological approaches appeared not to explain the high heterogeneity of our copper meta-analysis. Therefore, when investigating trace elements, covariants such as age and sex have to be taken into account in the analyses. In the light of these findings, we suggest that the possible alteration of serum zinc and copper levels are involved in the pathogenesis of AD.

---

### Integrated elemental analysis supports targeting copper perturbations as a therapeutic strategy in multiple sclerosis [^11183WVC]. Neurotherapeutics (2024). Medium credibility.

The fundamental requirement for copper in neurological function is exemplified by Menkes disease where mutations affecting the copper transporter ATP7A result in systemic copper deficiency, cuproenzyme dysfunction, neurodegeneration, and premature death. Mutations affecting ATP7A also cause occipital horn syndrome and a rare form of adult-onset motor neuropathy, further emphasising the need for available copper in the CNS. A heightened sensitivity of the CNS to copper perturbations is consistent with its naturally slow turnover rate within the CNS compared to peripheral tissues. This is particularly evident in the context of the neurodegenerative disease amyotrophic lateral sclerosis (ALS) where ubiquitous over-expression of mutant SOD1 in transgenic mice creates an elevated requirement for copper, and while peripheral tissues are able to meet this demand, the CNS does not. Consequently, mutant SOD1 accumulates in a copper-deficient state in these mice over time selectively in the CNS. Conversely, excessive copper levels in the CNS are also pernicious as demonstrated in Wilson's disease in which mutations to the copper transporter ATP7B result in abnormal CNS copper deposition and neurodegeneration. Ultimately, the CNS relies upon a fine balance of copper levels where pathological alterations have the capacity to drive a wide range of neurological problems.

---

### A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 practice guidance on Wilson disease from the American Association for the Study of Liver Diseases [^112nwCdW]. Hepatology (2025). High credibility.

Wilson disease — zinc treatment targets and overtreatment: Adequacy of zinc treatment is assessed by 24-h urinary copper excretion, which should be < 100 μg (< 1.6 μmol)/24 h on stable treatment; alanine aminotransferase (ALT) normalization may be a good marker and correlates with maintaining 24-h urinary copper below 100 μg/24 h, and elevated NCC normalizes with effective treatment. Overtreatment is suspected when urinary copper is very low (< 20 μg [< 0.3 μmol]/24 h) with low serum copper and lower ceruloplasmin, necessitating dose reduction or brief interruption if other hematologic or neurologic side effects occur; neurological changes are uncommon but may develop when depletion is severe and prolonged, usually after 5–15 years or more of treatment.

---

### Hepatic dry copper weight in pediatric autoimmune liver disease [^114GpNHQ]. Journal of Pediatric Gastroenterology and Nutrition (2023). Medium credibility.

Objectives

Elevated hepatic dry copper weight is recognized in adults with autoimmune liver disease (AILD) and chronic cholestasis. We aim to review hepatic dry copper weight in pediatric AILD.

Methods

Retrospective review of pediatric AILD managed at our institution from 1999 to 2018, and 104 patients with hepatic dry copper weight assessment were included.

Results

Median age at presentation was 13.4 years (interquartile range, IQR, 11.7–14.9), 60% female, 54% autoimmune hepatitis, 42% autoimmune sclerosing cholangitis, and 4% primary sclerosing cholangitis. Histological features of advanced liver fibrosis in 68%. Median hepatic dry copper weight was 51.1 µg/g dry weight (IQR, 28.0–103.8). Elevated hepatic dry copper weight (> 50 µg/g dry weight) was present in 51%, and was not associated with AILD subtype (P = 0.83), age at presentation (P = 0.68), or advanced fibrosis (P = 0.53). Liver transplantation (LT) was performed in 10%, who had higher hepatic dry copper weight (148.5 µg/g dry weight [IQR, 39.5–257.3] vs 47.5 [IQR, 27.8–91.5], P = 0.04); however this was not associated with LT on multivariate analysis (hazard ratio 1.002, 95% CI 0.999–1.005, P = 0.23). In 8 (7.7%) patients ATP7B was sequenced and potentially disease causing variants were identified in 2 patients, both who required LT.

Conclusions

Elevations in hepatic dry copper weight are common in pediatric AILD. Unlike in adults, it is not associated with AILD subtypes with cholestasis. Higher dry copper weight was detected in patients who required LT. While further work is needed to identify the significance of copper deposition in pediatric AILD, we recommend close monitoring of patients with elevated levels for progressive liver disease.

---

### Role of copper in human neurological disorders [^114ZHdzm]. The American Journal of Clinical Nutrition (2008). Low credibility.

Copper is a trace element present in all tissues and is required for cellular respiration, peptide amidation, neurotransmitter biosynthesis, pigment formation, and connective tissue strength. Copper is a cofactor for numerous enzymes and plays an important role in central nervous system development; low concentrations of copper may result in incomplete development, whereas excess copper maybe injurious. Copper may be involved in free radical production, via the Haber-Weiss reaction, that results in mitochondrial damage, DNA breakage, and neuronal injury. Evidence of abnormal copper transport and aberrant copper-protein interactions in numerous human neurological disorders supports the critical importance of this trace metal for proper neurodevelopment and neurological function. The biochemical phenotypes of human disorders that involve copper homeostasis suggest possible biomarkers of copper status that may be applicable to general populations.

---

### A systematic review and evidence-based guideline for diagnosis and treatment of menkes disease [^114MMou2]. Molecular Genetics and Metabolism (2019). Medium credibility.

Menkes disease is a rare X-linked neurodegenerative disorder caused by defect in copper metabolism. Parenteral copper supplementation has been used as a potential disease-modifying treatment of Menkes disease for decades. However, recent evidence suggests its efficacy only when treatment is started within days after birth, which also has important implications related to the techniques that enable early diagnosis. We aim at proposing a guideline for prenatal and neonatal diagnosis and for disease-modifying treatment of Menkes disease, guided by a systematic review of the literature, and built in conjunction with medical experts, methodologists and patient representatives. Thirteen articles were used for our recommendations that were based on GRADE system. Reviewed evidence suggests that prenatal genetic diagnosis in families with previous diagnosis of Menkes disease is feasible; analysis of plasma catecholamine levels is accurate for neonatal diagnosis of Menkes disease; treatment with copper-histidine is effective to increase survival and reduce neurologic burden of the disease if initiated in the neonatal period; and, treatment indication should not be guided by patient's genotype. In conclusion, our guideline can contribute to standardize some aspects of the clinical care of patients with Menkes disease, especially reducing disease burden and mortality and providers' and families' anxiety.

---

### Low hepatic tissue copper in pediatric nonalcoholic fatty liver disease [^115FQDor]. Journal of Pediatric Gastroenterology and Nutrition (2017). Low credibility.

Objective

Animal models and studies in adults have demonstrated that copper restriction increases severity of liver injury in nonalcoholic fatty liver disease (NAFLD). This has not been studied in children. We aimed to determine if lower tissue copper is associated with increased NAFLD severity in children.

Methods

This was a retrospective study of pediatric patients who had a liver biopsy including a hepatic copper quantitation. The primary outcome compared hepatic copper concentration in NAFLD versus non-NAFLD. Secondary outcomes compared hepatic copper levels against steatosis, fibrosis, lobular inflammation, balloon degeneration, and NAFLD activity score (NAS).

Results

The study analysis included 150 pediatric subjects (102 with NAFLD and 48 non-NAFLD). After adjusting for age, body mass index z score, gamma glutamyl transferase, alanine aminotransferase, and total bilirubin, NAFLD subjects had lower levels of hepatic copper than non-NAFLD (P = 0.005). In addition, tissue copper concentration decreased as steatosis severity increased (P < 0.001). Copper levels were not associated with degree of fibrosis, lobular inflammation, portal inflammation, or balloon degeneration.

Conclusions

In this cohort of pediatric subjects with NAFLD, we observed decreased tissue copper levels in subjects with NAFLD when compared with non-NAFLD subjects. In addition, tissue copper levels were lower in subjects with nonalcoholic steatohepatitis, a more severe form of the disease, when compared with steatosis alone. Further studies are needed to explore the relationship between copper levels and NAFLD progression.

---

### Copper modulation and memory impairment due to hippocampal tau pathology [^117ASdQZ]. Journal of Alzheimer's Disease (2020). Medium credibility.

Background:Environmental copper has been implicated in the pathogenesis of Alzheimer's disease based on evidence that: 1) brain copper levels increase with age, 2) copper promotes misfolding and toxicity of amyloid-β in vitro, 3) copper-modulating interventions reduce amyloid pathology in animal models. However, the effect of copper upon non-amyloid Alzheimer's pathology is relatively under-explored. Objective:To determine if modulation of brain copper level affects brain tau pathology and/or associated cognitive impairment. Methods:We tested the hypothesis that brain copper modulates tau pathology by manipulating brain levels of copper in the PS19 transgenic mouse model of tau pathology. We treated PS19 and wild-type mice with oral zinc acetate, an established therapy for long term control of excess brain copper, and examined treatment effects upon brain copper, brain tau, NFT-like pathology, and spatial memory. We treated a second cohort of mice with exogenous dietary copper in order to evaluate whether excess environmental copper promotes brain tau pathology. Results:Copper-lowering with oral zinc attenuated spatial memory impairment in female but not male PS19 mice, without a significant effect upon tau pathology. Copper loading increased brain copper, but did not have an effect on brain tau pathology or spatial memory function. Conclusion:These findings suggest that a strategy to lower brain copper may be viable for symptomatic benefit in the setting of tau neuropathology, but unlikely to have robust effects on the underlying pathology. These findings are consistent with dietary or other exogenous copper being unlikely to promote tau pathology.

---

### A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 practice guidance on Wilson disease from the American Association for the Study of Liver Diseases [^111s29VH]. Hepatology (2025). High credibility.

Chelation therapy treatment targets in Wilson disease (WD) — Adequacy of treatment is monitored by clinical and biochemical improvement and by measuring 24-h urinary copper excretion on treatment, which is highest immediately after starting treatment, when it may exceed 1000–2000 μg/24 h. With chronic (maintenance) treatment, urinary copper excretion should be approximately 200–500 μg/24 h (3–8 μmol/24 h), and serum NCC shows normalization with effective treatment. Values of 24-h urinary copper excretion > 500 μg/24 h in treated patients previously excreting 200–500 μg/24 h suggest nonadherence to medication or excessive liberalization of dietary copper; urinary copper excretion < 100 μg/24 h may signal overtreatment, particularly when serum copper and CuEXC are very low, as is the NCC (typically ≤ 5 μg/dl). In those nonadherent to D-penicillamine therapy, serum copper and CuEXC are elevated, and NCC may be elevated (> 25 μg/dl). With D-penicillamine treatment, serum ceruloplasmin may decrease and remain low or increase during chronic treatment, whereas a decrease in chronically treated patients may indicate overtreatment and is often associated with neutropenia, sideroblastic anemia, and hemosiderosis.

---

### Molecular pathogenesis of Wilson and menkes disease: correlation of mutations with molecular defects and disease phenotypes [^114nPGyx]. Journal of Medical Genetics (2007). Low credibility.

The trace metal copper is essential for a variety of biological processes, but extremely toxic when present in excessive amounts. Therefore, concentrations of this metal in the body are kept under tight control. Central regulators of cellular copper metabolism are the copper-transporting P-type ATPases ATP7A and ATP7B. Mutations in ATP7A or ATP7B disrupt the homeostatic copper balance, resulting in copper deficiency (Menkes disease) or copper overload (Wilson disease), respectively. ATP7A and ATP7B exert their functions in copper transport through a variety of interdependent mechanisms and regulatory events, including their catalytic ATPase activity, copper-induced trafficking, post-translational modifications and protein-protein interactions. This paper reviews the extensive efforts that have been undertaken over the past few years to dissect and characterise these mechanisms, and how these are affected in Menkes and Wilson disease. As both disorders are characterised by an extensive clinical heterogeneity, we will discus how the underlying genetic defects correlate with the molecular functions of ATP7A and ATP7B and with the clinical expression of these disorders.

---

### A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 practice guidance on Wilson disease from the American Association for the Study of Liver Diseases [^113zXxc4]. Hepatology (2025). High credibility.

Guidance statements 23–24 — overtreatment thresholds and actions indicate that overtreatment may be signaled by cytopenias or retention of tissue iron with raised serum ferritin and is confirmed by a low serum copper and a very low 24-h urinary copper output; for oral chelators, 24-h urinary copper excretion below the therapeutic target, specifically < 100 μg/24 h or < 1.6 μmol/24 h, suggests overtreatment, and for zinc therapy, 24-h urinary copper < 20 μg/24 h (< 0.3 μmol/24 h) suggests overtreatment. Once overtreatment is confirmed, dose reduction or brief interruption of medical therapy should be instituted with close follow-up for reassessment. Treatment failure may occur during treatment initiation or chronic therapy; concurrent diseases and nonadherence must be excluded; and pharmacological therapy should be changed or adjusted to correct treatment failure, with liver transplantation potentially required for more advanced liver disease or liver failure.

---

### Integrated elemental analysis supports targeting copper perturbations as a therapeutic strategy in multiple sclerosis [^117CCLaQ]. Neurotherapeutics (2024). Medium credibility.

In the context of MS, excess copper has been implicated in white matter demyelination and oligodendrocyte loss due to an upregulation of copper transporters CTR1, ATP7A, and ATP7B by activated astrocytes prompting copper uptake and release. These localised changes to disease-affected white matter regions were observed in both human MS cases and mouse models of MS, including EAE and cuprizone-treated mice. Here, we show that while bulk copper is elevated in the MS spinal cord, further analyses reveal nuanced shifts in copper distribution. In particular, while the white matter indicated an increase in copper levels in support of previously reported changes to copper transporter expression, the ventral grey matter displayed a marked decrease. These observations harbour similarities to those recently reported for the ALS-affected spinal cord which also showed an elevation in white matter copper coupled with a decrease in the ventral grey matter. Why the white and grey matter are differentially affected remains to be established. Nonetheless, these results indicate a complexity of copper metallobiology beyond mere excess and deficiency in MS and broader neurodegeneration. This is congruent with our observation of decreased copper levels in TBS-soluble extracts of spinal cord tissue yet elevated levels of copper in the TBS-insoluble fraction. The TBS-soluble fraction is enriched for cytoplasmic proteins (Additional file 1: Fig. S1), and as copper trafficking proteins responsible for metallation of cuproenzymes reside in the cytoplasm, diminished levels of copper in this fraction could support a decreased amount of bioavailable copper which is reflected in the perturbed activities of cuproenzymes in MS. Conversely, it is conceivable that in MS where lesions are formed that copper becomes associated with insoluble components of these lesions. Analogous sequestration of copper into biologically inaccessible pools is described for the Alzheimer's disease-affected brain where copper accumulates in extracellular amyloid plaques. Sequestration into a biologically inaccessible pool having an impact on copper-dependent processes within the CNS is in line with the natural turnover of copper being particularly slow in the CNS when compared to other tissues. In other words, accumulation of copper within the white matter and/or TBS-insoluble fraction in MS would directly affect copper-dependent processes in other regions or fractions because the CNS has limited capacity to respond to altered copper requirements. The factors that prompt biochemical and spatial redistribution of copper in MS require further exploration.

---

### Prion protein promotes copper toxicity in Wilson disease [^1161Gp8c]. Nature Communications (2025). High credibility.

Introduction

Copper (Cu) is an indispensable micronutrient for the growth and replication of all eukaryotic organisms. By exploiting the ability of copper to switch between Cu⁺ and Cu²⁺ oxidation states, cuproenzymes drive vitally important metabolic processes including respiration, anti-oxidant defense, biosynthesis of neuropeptides, and components of connective tissue. However, excess copper represents a serious danger for cells and organisms due to the ability of Cu to provoke extensive damage via activation of specific cell death mechanisms –. Thus, cells and organisms have evolved a finely tuned network of transporters and copper-binding proteins to provide a sufficient supply of the metal and to avoid toxicity.

A failure of this regulatory network to properly support Cu homeostasis manifests in serious life-threatening disorders. Mutations in transporters, which drive adsorption of dietary Cu, cause severe systemic Cu deficiencies. Altered expression of Cu transporters in several cancers has been also associated with elevated Cu supply, fueling different processes that support tumor growth. Finally, Cu toxicity occurs in Wilson disease (WD), which is caused by mutations in the ATP7B gene encoding a hepatic Cu transporter that drives excretion of excess Cu to the bile. Loss of ATP7B function leads to Cu accumulation initially in the liver and subsequently in the brain thereby causing serious hepatic and neurological abnormalities culminating in death. Approved treatments for WD have serious drawbacks in a substantial cohort of patientsbut the development of new therapeutic strategies is hampered by the poor understanding of the molecular mechanisms that can be exploited to normalize Cu homeostasis.

---

### Empirical evidence for biometal dysregulation in Parkinson's disease from a systematic review and bradford hill analysis [^111996xr]. NPJ Parkinson's Disease (2022). Medium credibility.

Assignment of studies investigating copper in Parkinson's disease to Bradford Hill criteria

Twenty-five full-text articles reporting quantitative studies of copper levels in the SN, and copper-associated pathways, in Parkinson's disease (Supplementary Tables 1 and 3) were analyzed in an identical manner. The number of studies investigating alterations in nigral copper levels in Parkinson's disease was substantially lower than those examining iron in this disorder, precluding definitive conclusions for some criteria. Almost two-thirds of the articles reporting copper data (n = 16 of 25 studies, 64%) also reported data for iron in the same samples.

Evidence drawn from high quality studies investigating copper in Parkinson's disease (n = 6) supported three of the nine Bradford Hill criteria (plausibility, temporality, coherence; Fig. 3a, Supplementary Table 3). Evidence for the remaining five criteria was considered equivocal, primarily because of the limited number of high quality studies addressing these criteria. No data was available for the ninth criterion, experiment, as there are yet no published articles on copper-modulating therapies in Parkinson's disease patients. The addition of data from moderate quality studies (n = 19) subsequently allowed us to conclude that available data also support the criteria of specificity, biological gradient and analogy (Supplementary Table 3). In contrast, the addition of moderate quality studies to the remaining two criteria, strength and consistency, opposed a relationship between copper dysregulation and Parkinson's disease.

Fig. 3
Bradford Hill criteria data and outcomes of all included articles investigating alterations in SN copper levels, or levels of cuproproteins or copper-associated genes in Parkinson's disease.

a Portrays results obtained from high quality articles alone, whereas b depicts the combined results from high and moderate quality articles. c All articles reporting alterations in copper metal levels in the Parkinson's disease SN or SNc, that is, excluding articles reporting protein and/or genetic changes. Data for the Bradford Hill criterion, coherence, is considerably higher than other criteria and was therefore presented in Supplementary Table 3. Letters S (supporting), O (opposing), and E (equivocal) indicate overall criteria outcomes determined by analyses of all included studies. Non-bolded letters highlight discrepant criteria outcomes between each panel and (a). N, no data.

---

### Copper hypothesis in the missing hereditability of sporadic Alzheimer's disease: ATP7B gene as potential harbor of rare variants [^115xZVYQ]. Journal of Alzheimer's Disease (2012). Low credibility.

Sporadic Alzheimer's disease (LOAD) is the most common form of dementia and has a high heritability. The genes associated with LOAD explain a small proportion of the genetic contribution to LOAD, leaving several genetic risk factors to be identified. Some authors have suggested a shift from the paradigm "common disease-common gene variants", which is currently the basis for genome-wide association studies, to a "common disease-multiple rare gene variants" hypothesis aimed at identifying rarer allele variants with large effect size on LOAD onset, suggesting that they may account for the 'missing' heritability of LOAD. Recent studies have demonstrated the connection between copper imbalance and LOAD. Some studies have pointed out the pivotal role of 'free' copper, the portion of serum copper non-bound to ceruloplasmin. Free copper has been already identified as a biological marker of Wilson's disease (WD), the paradigmatic disease of free copper toxicosis or accumulation. The ATP7B gene controls free copper levels, and its mutations cause WD. The paradigm shift to "common disease-multiple rare variants" may suitably fit the ATP7B gene; the high heterogeneity of the ATP7B gene may have hidden multiple rare variants with large effect sizes for LOAD. Demonstrating that the ATP7B gene harbors rare variants which may account for some of the missing hereditability of LOAD would support previous evidence of copper involvement in LOAD from a new and totally different perspective and would bring almost immediate benefits in the clinical community in terms of early diagnosis, treatment efficacy, LOAD prevention, and cost savings.

---

### Bariatric nutrition and evaluation of the metabolic surgical patient: update to the 2022 Obesity Medicine Association (OMA) bariatric surgery, gastrointestinal hormones, and the microbiome clinical practice statement (CPS) [^1139X5Bt]. Obesity Pillars (2025). High credibility.

Micronutrient laboratory testing for metabolic and bariatric surgery (MBS) patients — Preoperative and post-surgery micronutrient laboratory reports can provide evidence of mild to severe nutrient deficiencies and excessive nutrient storage, and abnormal micronutrient laboratory tests paired with physical signs or neurological symptoms can provide an accurate nutritional assessment of nutrient stores. Clinicians should be aware of confounding conditions that may impact micronutrient status, including elevated vitamin A associated with acute ingestion of ethanol or a non-fasting state; low zinc level influenced by infection, inflammation, stress, oral contraceptives or pregnancy; elevated zinc due to supplementation that may interfere with copper absorption; elevated copper in response to infection, inflammation, stress, copper supplementation, oral contraceptives, or pregnancy; reduced serum copper with corticosteroids, zinc, malnutrition, or malabsorption; and falsely high serum vitamin B12 levels observed in myeloproliferative disease, acute hepatitis, severe alcoholic liver disease, and cirrhosis. Taking high doses of supplements and not withholding supplements for at least 24 hours prior to blood draws may artificially elevate micronutrient levels.

---

### Elevation of serum copper levels in Alzheimer's disease [^116LXH7E]. Neurology (2002). Low credibility.

Objective

To determine whether serum trace metals and oxidative species are related to abnormal cognition in AD.

Methods

The authors studied serum peroxides, copper, iron, transferrin, and antioxidant capacity in 79 patients with AD (mean age 74.3 years; 25 men, 54 women) and in 76 cognitively normal individuals (mean age 70.1 years; 33 men, 43 women). The relation of these oxidative and trace metals to APOE epsilon4 allele frequency, neuropsychological performance, and cerebrovascular or atrophic burden, as estimated by brain MRI and ultrasonography of cerebral vessels, was evaluated.

Results

Copper level was higher (p < 0.001) in subjects with AD than control subjects (specificity = 95%, sensitivity = 60%) with a cutoff serum level of 16 micro mol/L (1.02 mg/L). An increase of 1 micro mol/L in serum copper accounted for 80% of the risk of having AD and correlated with poor neuropsychological performance and medial temporal lobe atrophy (p < 0.03). Antioxidant capacity decreased and correlated with medial temporal lobe atrophy (p < 0.009) and with APOE epsilon4 allele (p = 0.004).

Conclusions

Copper may play a role in neurodegenerative processes in AD, and serum copper measurement may prove to be a peripheral diagnostic marker for AD.

---

### Integrated elemental analysis supports targeting copper perturbations as a therapeutic strategy in multiple sclerosis [^116LBbUy]. Neurotherapeutics (2024). Medium credibility.

A salient consideration for the use of copper modulating compounds as a therapeutic strategy that merits caution is the prospect of toxicity arising from excess copper levels. In MS, this concept has been investigated showing that white matter pathology involves increased expression of copper transporters associated with activated astrocytes and that copper released by astrocytes is harmful to oligodendrocytes. Additionally, excess copper has been found to drive aggregation of lipoylated mitochondrial proteins through direct interaction with the lipoyl moiety with toxic repercussions. Taking these factors into account, ensuring prospective copper modulating therapies avoid unintended toxic consequences resulting from excess will be of paramount importance. An advantage of Cu II (atsm) lies in its chemistry where its copper modulating properties are dictated by conditions related to a perturbed intracellular redox environment. In the clinic, isotopically labelled Cu II (atsm) has been used to image affected CNS regions of patients with neurodegenerative disease including ALS and Parkinson's disease. Selective retention of the Cu II (atsm)-delivered, PET-detectable copper signal in affected regions of the CNS is attributed to alterations to the cellular redox environment associated with pathology in these diseases. Although copper associated with Cu II (atsm) is detectable in peripheral tissue, preferential retention and copper modulating actions where it is required is supported by the ability to restore cuproenzyme functionality in disease-affected regions. These properties are likely to provide benefit in contrast to other copper related agents that are characterised by a higher propensity towards copper release under physiological conditions.

The involvement of neurodegeneration in the worsening of permanent neurological disability in MS underscores the necessity for neuroprotection in therapeutic regimens. Progress on this front, however, has been limited to date with new approaches required through an expanded understanding of potential therapeutic targets amenable to pharmacological intervention. Here, we describe copper perturbations as a broad disease feature of MS and provide initial preclinical outcomes in the EAE model supporting a neuroprotective role for Cu II (atsm). These findings highlight a role for altered copper biology in MS and suggest that further investigation of Cu II (atsm) is warranted as a potential therapeutic treatment for neurodegeneration in MS.

---

### A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 practice guidance on Wilson disease from the American Association for the Study of Liver Diseases [^114W7Rif]. Hepatology (2025). High credibility.

Wilson disease (WD) — nutrition and dietary copper: The average diet is replete with copper and serves as the source of copper for replenishing normal losses of this trace element.

---

### Biometals and their therapeutic implications in Alzheimer's disease [^113U3kwe]. Neurotherapeutics (2015). Low credibility.

No disease modifying therapy exists for Alzheimer's disease (AD). The growing burden of this disease to our society necessitates continued investment in drug development. Over the last decade, multiple phase 3 clinical trials testing drugs that were designed to target established disease mechanisms of AD have all failed to benefit patients. There is, therefore, a need for new treatment strategies. Changes to the transition metals, zinc, copper, and iron, in AD impact on the molecular mechanisms of disease, and targeting these metals might be an alternative approach to treat the disease. Here we review how metals feature in molecular mechanisms of AD, and we describe preclinical and clinical data that demonstrate the potential for metal-based drug therapy.

---

### Integrated elemental analysis supports targeting copper perturbations as a therapeutic strategy in multiple sclerosis [^115xaqcU]. Neurotherapeutics (2024). Medium credibility.

In line with the human MS spinal cord, levels of copper were found to be decreased in the TBS-soluble fraction of the EAE spinal cord, but in contrast with changes seen for the MS spinal cord, the EAE mice also showed a decrease in TBS-insoluble copper levels (Fig. 4 a). These copper changes translated into gene expression differences with 14 of the 20 measured copper-handling genes displaying altered expression in the EAE spinal cord (Fig. 4 b and c; Additional file 1: Fig. S6). Whilst the EAE copper-handling gene expression profile showed differences compared to human MS, these analyses demonstrate that copper perturbations are observed in both human cases and the model of disease.

Consistent with the cuproenzyme changes observed in human MS, ceruloplasmin levels were elevated despite a decrease in total ferroxidase activity, while hephaestin levels were unchanged (Fig. 5 a–c). Similarly, DβH protein levels were elevated without a commensurate increase in activity (Fig. 5 d and e) while LOX and LOXL3 levels were decreased and increased, respectively, translating into unchanged levels of overall LOX activity (Fig. 5 f–h). To assess whether this functional cuproenzyme output could be restored pharmacologically, EAE mice were also treated with Cu II (atsm) resulting in a normalisation of protein and activity levels (Fig. 5 a–h) alongside augmented copper levels (Additional file 1: Fig. S7a). Together, these results show broad commonalities across model and disease in terms of functional copper-dependent changes associated with spinal cord copper perturbations. Moreover, initial support is provided for being able to target these functional outputs pharmacologically in an MS context using the copper-modulating compound Cu II (atsm).

---

### ACG clinical guideline: evaluation of abnormal liver chemistries [^1122RDkF]. The American Journal of Gastroenterology (2017). Medium credibility.

Wilson disease evaluation — patients with persistently elevated AST/ALT should undergo initial serum ceruloplasmin testing; "Screening should be considered in all patients with persistently elevated AST/ALT levels, and consists of serum ceruloplasmin testing (56)". If ceruloplasmin is low, "confirmatory testing should be pursued including 24-h urine copper and/or serum copper levels, slit-lamp eye examination to identify pathognomonic Kayser-Fleischer rings, and possible liver biopsy to confirm the diagnosis, stage liver fibrosis, and quantify hepatic copper overload to guide management". Molecular testing can be used when needed, as "Molecular genetic analyses for the ATP7B mutation can be pursued in cases of diagnostic uncertainty", and genetic heterogeneity is noted: "Over 32 different mutations of the Wilsons gene have now been identified and unlike hemochromatosis, there is no predominant mutation".

---

### PTPN2 copper-sensing relays copper level fluctuations into EGFR / CREB activation and associated CTR1 transcriptional repression [^113aTFF2]. Nature Communications (2024). High credibility.

Introduction

Copper is an essential nutrient in the human diet with prototypical roles as metalloenzyme cofactors; however, excess copper induces cellular (redox) stress via formation of reactive oxygen/nitrogen species. Relatedly, the biochemical mechanisms regulating intracellular copper levels have been extensively characterized. There are two mammalian copper importers; the cuprous importer CTR1 (encoded by the SLC31A1 gene) — responsible for the vast majority of copper internalization — and the cupric importer DMT1 (encoded by the SLC11A2 gene). For expediency, we hereafter refer to the SLC31A1 and SLC11A2 genes and transcripts as CTR1 and DMT1, respectively. Following reduction to Cu¹⁺ and import, copper is shuttled inside the cell by chaperone proteins (e.g. ATOX1) to subcellular locations for metallocofactor assembly or export.

Copper influx and efflux stimulate a wide range of human cellular responses, including cuproplasia (copper dependent cell growth and proliferation), cuproptosis, neuronal activities –, cell differentiation, and the epithelial to mesenchymal transition in cancer, as well as signaling pathways such as cyclic adenosine monophosphate (cAMP) signaling, MAPK/ERK, JAK-STAT, PI3K/Akt, NF-κB, and the NOD-like receptor protein 3 (NLRP3) inflammasome. Furthermore, copper dyshomeostasis causes human diseases such as Menkes syndrome and Wilson disease, and elevated copper levels induce numerous pro-cancer activities (e.g. angiogenesis, metastasis, and cell proliferation). Relatedly, serum and tissue copper levels correlate with carcinogenesis and prognosis across diverse cancers. Targeting copper homeostasis pathways has been proposed as promising therapeutic approaches against diverse diseases, including cancer.

---

### Wilson's disease in children: a position paper by the hepatology committee of the European society for paediatric gastroenterology, hepatology and nutrition [^114hoBJW]. Journal of Pediatric Gastroenterology and Nutrition (2018). Medium credibility.

Regarding specific circumstances for Wilson's disease, more specifically with respect to pediatric patients, diagnostic evaluation, ESPGHAN 2018 guidelines recommend to consider assessing the copper content in the liver tissue in pediatric patients where the diagnosis is uncertain.

---

### Linking Parkinson's disease and melanoma: the impact of copper-driven cuproptosis and related mechanisms [^113LUyoc]. NPJ Parkinson's Disease (2025). Medium credibility.

In this study, an intersection analysis of DEGs between PD and melanoma datasets uncovered both significant overlaps and important distinctions, indicating potential shared molecular signatures. These overlapping genes point to common biological pathways, with notable enrichment in pathways involving cation or monoatomic ion channels and the transmembrane transport of monoatomic or metal ions. Of particular interest, melanin, and neuromelanin are synthesized from tyrosine through the copper-dependent enzyme tyrosinase, highlighting the essential role of metal ion transport in maintaining appropriate copper levels in both dopaminergic neurons and melanocytes. This copper homeostasis is crucial not only for supporting biosynthetic processes but also for preventing melanocyte death and preserving SOD1 activity, which has been shown to protect against neuronal loss in PD. One of the most compelling findings of our study is the shared involvement of cuproptosis pathways in the neurons affected by PD and the melanocytes associated with melanoma. Disruptions in metal ion transport that lead to copper overload may contribute to the pathogenesis of PD through copper-dependent PCD in dopaminergic neurons. This finding aligns with evidence from Wilson disease — a genetic disorder marked by defective copper metabolism that causes copper accumulation in the brain and other organs. The neurological symptoms of Wilson's disease, such as tremors, rigidity, and bradykinesia, resemble those in PD, suggesting a significant role of copper dysregulation in movement-related brain damage. Furthermore, elevated free copper in PD has been associated with oxidative stress, alpha-synuclein aggregation, and increased iron in affected brain regions, all of which are linked to intensified neuronal damage. Together, these findings underscore the importance of copper homeostasis in both PD and melanoma, with potential implications for copper-focused therapeutic strategies in neurodegenerative and oncological contexts.

---

### A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 practice guidance on Wilson disease from the American Association for the Study of Liver Diseases [^112uLKZP]. Hepatology (2025). High credibility.

Wilson disease — zinc adherence and monitoring: Adherence to long-term zinc therapy can be challenging because the three-times-daily dosing must be strictly away from meals, and clinical monitoring needs to be stringent. Rise in serum aminotransferases may be an early sign of poor adherence or treatment failure, increased 24-h urinary copper excretion suggests poor adherence or increased dietary copper intake, and urinary zinc can be checked for adherence with target values of > 1–2 mg/24 h.

---

### Metals and Alzheimer's disease: how far have we come in the clinic? [^116dXQHD]. Journal of Alzheimer's Disease (2018). Low credibility.

CONCLUSION

There is an abundance of preclinical in vitro and in vivo evidence to support the role of transition metals, such as copper, zinc, and iron, in both the onset and progression of neurodegenerative disorders such as AD. Furthermore, there is strong evidence that these metals are also critically involved in cellular processes that mediate neuronal/brain health, with specific interactions on key pathways responsible for functional outcomes such as learning and memory (in both healthy and pathological states). As such, the natural extension of these preclinical studies has involved translation into human clinical trials. Unfortunately for the field, as the area of "metals and Alzheimer's disease" remains a niche area of interest from both a wet bench, but also bedside, perspective — then there has continued to be only limited support available to a small number of groups/companies to pursue these concepts. As such, many of the interventional trials that have been conducted to date have been underpowered or otherwise compromised in some way such that we still have yet to see a sufficiently rigorous, in-depth, and controlled study completed that would definitively answer the question of whether targeting metal dyshomeostasis in the AD brain is an efficacious therapeutic approach worth pursuing. Confounding the field of course, is the issue that the clinical trials that have been conducted have taken very different therapeutic approaches, either supplementing, chelating, or modulating a variety of metals (be it copper, zinc, iron, or some other metal or combination thereof). Given the complex interplay between different metals and the multitude of metal:protein interactions that subserve critical cellular pathways, not to mention the heterogeneous nature of AD and the likely non-linear change in metals that will occur across both age and the course of the disease (and which may be different depending on whether the disease is progressing or slowed/halted), then arguably there may be too many variables to ever allow a single "definitive" trial to be conducted.

In an environment of limited funding, largely characterized by small "snapshot" style clinical trials, we can only hope that incremental investigator driven trials can provide sufficiently compelling data to generate excitement in this space that will prompt a significant investment from the biotech sector to facilitate the large scale human trials that are required to properly interrogate the potential therapeutic efficacy of metal targeting compounds in AD.

---

### Effect of cerebral amyloid angiopathy on brain iron, copper, and zinc in Alzheimer's disease [^115anj5H]. Journal of Alzheimer's Disease (2011). Low credibility.

Cerebral amyloid angiopathy (CAA) is a vascular lesion associated with Alzheimer's disease (AD) present in up to 95% of AD patients and produces MRI-detectable microbleeds in many of these patients. It is possible that CAA-related microbleeding is a source of pathological iron in the AD brain. Because the homeostasis of copper, iron, and zinc are so intimately linked, we determined whether CAA contributes to changes in the brain levels of these metals. We obtained brain tissue from AD patients with severe CAA to compare to AD patients without evidence of vascular amyloid-β. Patients with severe CAA had significantly higher non-heme iron levels. Histologically, iron was deposited in the walls of large CAA-affected vessels. Zinc levels were significantly elevated in grey matter in both the CAA and non-CAA AD tissue, but no vascular staining was noted in CAA cases. Copper levels were decreased in both CAA and non-CAA AD tissues and copper was found to be prominently deposited on the vasculature in CAA. Together, these findings demonstrate that CAA is a significant variable affecting transition metals in AD.

---

### Empirical evidence for biometal dysregulation in Parkinson's disease from a systematic review and bradford hill analysis [^116c43eg]. NPJ Parkinson's Disease (2022). Medium credibility.

The potential consequences of low brain copper levels can be inferred from analogous copper changes in other neurological disorders. In Menkes disease, a genetic loss-of-function mutation in the copper transport protein ATP7A results in a systemic copper deficiency, including in the central nervous system. Motor dysfunction and neurodegeneration characteristic of Menkes disease are considered to result from inadequate copper loading, and subsequent dysfunction of, cuproproteins mediating essential biological functions for neuronal viability and survival. We posit that impaired cuproprotein structure and function, resultant from copper deficiency, constitutes a fundamental pathway to the degeneration of vulnerable neuronal populations in phenotypically distinct disorders.

Although in vitro studies have suggested that copper may contribute to disease etiology by stimulating oligomerization and deposition of α-synuclein, the depletion of cellular copper reserves in the Parkinsonian SN suggests that copper-mediated stimulation of synucleinopathy is unlikely to underlie neurodegeneration in this brain region. By contrast, we recently reported a wildtype Cu/Zn-superoxide dismutase (SOD1) proteinopathy associated with neuronal loss in the Parkinson's disease SN closely resembling misfolded SOD1 linked to neuronal death in SOD1-associated ALS spinal cord. The specificity of SOD1 misfolding and aggregation to copper-deficient brain regions is suggestive of perturbed copper delivery to other cuproproteins, especially those with a lower affinity to copper. Despite this evidence, an opposing conclusion is drawn for Bradford Hill's strength and consistency when considering SOD1 protein/gene on its own (Supplementary Table 5). This finding is influenced by the fact that four of these nine reported studies investigated specific mutations in SOD1 in Parkinson's disease patients which were not found to be present. While this suggests that a mutation in SOD1 is unlikely to be causally linked to Parkinson's disease it does not exclude other possible disease-linked mechanisms associated with this protein. The influence of genetic studies on Bradford Hill's criteria is also seen in the case of ferritin, transferrin, hemeoxygenase-1 and ceruloplasmin (Supplementary Table 5). Indeed, this highlights the importance of Bradford Hill's comment in his original work that none of the nine criteria provide indisputable evidence for or against causality; rather he stated that all available data must be considered in its totality. In part, this is a contributing factor to our inability to identify the metalloprotein and/or gene that is most causally associated with Parkinson's disease. More importantly, however, is that there is a limited number of studies that fulfilled individual criteria for the investigated proteins and genes, allowing us to draw conclusions for a maximum of five criteria for only a few of these proteins and genes (Supplementary Table 5). Further research into specific changes in individual metalloproteins and genes in Parkinson's disease is therefore required to support an argument of causality for any one protein or gene using the Bradford Hill model.

---

### A multidisciplinary approach to the diagnosis and management of Wilson disease: executive summary of the 2022 practice guidance on Wilson disease from the American Association for the Study of Liver Diseases [^113Kg9qc]. Hepatology (2023). High credibility.

Regarding diagnostic procedures for Wilson's disease, more specifically with respect to liver biopsy, AASLD 2022 guidelines recommend to recognize that hepatic parenchymal copper content > 250 mcg/g dry weight occurs in most patients, while a lower content still above normal occurs less frequently but should prompt another confirmatory testing. Exclude WD in case of normal hepatic copper content (< 50 mcg/g dry weight) in untreated patients.

---

### Empirical evidence for biometal dysregulation in Parkinson's disease from a systematic review and bradford hill analysis [^1179rWoQ]. NPJ Parkinson's Disease (2022). Medium credibility.

Interestingly, copper levels in the SN are two-fold higher than those in other regions of the healthy brain, suggesting this region has an increased demand for, and a higher capacity to accumulate, this biometal. Using synchrotron X-ray fluorescence microscopy, we showed the copper content of individual catecholaminergic SN and locus coeruleus neurons are significantly reduced in a putative preclinical form of Parkinson's disease, incidental Lewy body disease, suggesting this change is an early event in disease pathogenesis. These data suggest that the regional decrease in copper early in the Parkinson's disease brain may represent a biomarker for the disease process. In contrast to the accumulation of iron in multiple deep brain nuclei with varying levels of cell loss in the Parkinson's disease brain, the marked copper deficiency is restricted to regions of neuronal degeneration. Elemental analysis of metal concentrations in a progressive form of parkinsonism known as Parkinson's disease dementia demonstrated copper deficiency in seven out of nine investigated brain regions, whereas iron accumulation was not observed in any brain regions, highlighting the marked differences in patterns of defective metal levels during advanced stages of the disease. Currently, a tool for in vivo quantification of brain copper is not available but such a technology would be valuable to elucidate the spatiotemporal nature of copper changes and its relationship to clinical disease.

---

### Empirical evidence for biometal dysregulation in Parkinson's disease from a systematic review and bradford hill analysis [^1149mfC8]. NPJ Parkinson's Disease (2022). Medium credibility.

Methods

Search strategy and study selection

To identify eligible studies for assignment to Bradford Hill criteria, hereafter termed Bradford Hill analysis, we conducted a systematic review according to the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta Analyses (PRISMA) statement (Fig. 4). We performed an electronic search for research articles published online in PubMed, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL) and Scopus databases from inception until September 9th, 2019 using the terms " Parkinson* ", " copper ", Cu", " cupro* ", " copper protein? ", " iron ", " Fe ", " ferro* " and " iron protein? " (Supplementary Table 6). As Parkinson's disease does not develop naturally in other species, a filter for human studies was applied to the database searches. In the case of Scopus, the term "human" was added to its search strategy as a filter function was not available at the date of the search. Our search strategy generated 8,437 records collectively from all four databases. Duplicates were removed using a 12-step process modified from published literature (Supplementary Table 7). Titles and abstracts of the remaining 4,891 unique articles were independently screened by two authors (A. A. B.T.) according to pre-defined inclusion and exclusion criteria (Supplementary Table 8). Eligible studies reported quantitative and semi-quantitative data of iron and/or copper levels in the Parkinson's disease SN, investigated biochemical changes in the levels or function of predetermined genes and metalloproteins (Supplementary Table 9) in the Parkinson's disease SN, evaluated the therapeutic potential of interventions altering brain metal levels in Parkinson's disease patients, or investigated any of these variables of interest in regions of neuron death in other neurodegenerative disorders. Screening excluded a further 4612 studies. Complete texts of the remaining 279 studies were reviewed for eligibility, resulting in the exclusion of a further 98 studies that did not meet inclusion criteria (Fig. 4).

Fig. 4
PRISMA flowchart of literature search, screening, eligibility, and quality assessment.

CENTRAL The Cochrane Controlled Register of Controlled Trials.

---

### A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 practice guidance on Wilson disease from the American Association for the Study of Liver Diseases [^111mXwBw]. Hepatology (2025). High credibility.

Wilson disease (WD) dietary background — general principles: The recommended dietary allowance (RDA) for copper for healthy adults is 0.9 mg/day, and the median copper intake from foods in the United States is 1–1.6 mg/day; WD cannot be treated exclusively by dietary measures. For patients with WD, a few foods with very high concentrations of copper (nuts, chocolate, most shellfish, soy-based products, mushrooms, organ meats) should be avoided, at least in the first year of treatment, and health foods and supplements should be scrutinized for copper content.

---

### A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 practice guidance on Wilson disease from the American Association for the Study of Liver Diseases [^116JZRDb]. Hepatology (2025). High credibility.

Specific diagnostic challenges — congenital disorders of glycosylation (CDGs): In some CDGs, serum ceruloplasmin is low and liver biochemistries abnormal; hepatic copper concentrations are moderately elevated, typically > 50 but < 250 μg/g dry weight tissue, while basal 24-h urinary copper excretion is normal, and phosphoglucomutase 1 deficiency (PGM1-CDG) produces this clinical picture.

---

### Copper deficiency may be a leading cause of ischaemic heart disease [^112XFeEN]. Open Heart (2018). Low credibility.

Lipoproteins and copper

The oxidation of low-density lipoproteins (LDLs) is thought to play a significant role in atherosclerosis. Copper deficiency increases the susceptibility of both LDL and other lipoproteins (high-density lipoprotein (HDL) and very-low-density lioprotein (VLDL)) to oxidation. Lipoproteins from copper-deficient animals show increased formation of thiobarbituric acid reactive substances when exposed to oxidative reactions using iron, which indicates that copper may exert a protective effect against iron-induced oxidation. While copper ions can catalyse the oxidation of lipoproteins, copper is also a necessary component of enzymes that prevent oxidative modification, such as copper, zinc superoxide dismutase. Copper-deficient animals also show increases in glycated haemoglobin, although lipoproteins do not appear to be more glycated than controls. The mechanisms behind increased lipoprotein oxidation are not known with certainty, but may be related to the physicochemical properties of the lipoproteins, to decreased levels of copper-dependent antioxidant enzymes or to other factors.

Copper deficiency can also cause hypercholesterolemia, one mechanism for this being increased levels of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, a key enzyme in the cholesterol synthesis pathway. Notably, statin drugs used in the prevention and treatment of IHD interfere with the activity of HMG-CoA reductase and thus lower cholesterol levels. Rats that were made copper-deficient had a > 50% increase in total cholesterol and an increase in HMG-CoA reductase activity of 85% to 288%.

Copper deficiency can increase total cholesterol and increase the susceptibility of lipoproteins to oxidation, two key features that increase IHD risk. Dietary copper or copper supplementation may thus favourably impact these risk factors without any of the side effects often seen in drug treatment. Seen another way, perhaps high total cholesterol and oxidised lipoproteins seen in humans with increased IHD risk, or actual disease, are artefacts of lower body copper levels, which is the real risk factor.

---

### Cerebrospinal fluid metals and the association with cerebral small vessel disease [^116EWrbb]. Journal of Alzheimer's Disease (2020). Medium credibility.

Background

Brain metal homeostasis is essential for brain health, and deregulation can result in oxidative stress on the brain parenchyma.

Objective

Our objective in this study was to focus on two hemorrhagic MRI manifestations of small vessel disease [cerebral microbleeds (CMBs) and cortical superficial siderosis (cSS)] and associations with cerebrospinal fluid (CSF) iron levels. In addition, we aimed to analyze CSF biomarkers for dementia and associations with CSF metal levels.

Methods

This is a cross-sectional study of 196 patients who underwent memory clinic investigation, including brain MRI. CSF was collected and analyzed for metals, amyloid-β (Aβ) 42, total tau (T-tau), and phosphorylated tau (P-tau), and CSF/serum albumin ratios. Statistical analyses were performed using generalized linear models.

Results

No significant difference was found between CSF metal levels across diagnostic groups. Higher iron and copper levels were associated with higher CSF levels of Aβ42, T-tau, P-tau, and CSF/serum albumin ratios (p < 0.05). Zinc was associated with higher CSF/serum albumin ratios. There was no significant association between CMBs or cSS and CSF iron levels. An increase in CSF iron with the number of CMBs was seen in APOEɛ4 carriers.

Conclusion

CSF iron levels are elevated with cerebral microbleeds in APOEɛ4 carriers, with no other association seen with hemorrhagic markers of small vessel disease. The association of elevated CSF iron and copper with tau could represent findings of increased neurodegeneration in these patients.

---

### A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 practice guidance on Wilson disease from the American Association for the Study of Liver Diseases [^113zfm4Q]. Hepatology (2025). High credibility.

Wilson disease — monitoring and adherence assessment during therapy includes targeted examination, history, and laboratory surveillance. Physical examination should look for evidence of liver disease and neurological symptoms; for patients on D-penicillamine, cutaneous changes should be sought, and history should include questioning about psychiatric symptoms, especially depression. Repeat examination for KF rings should be performed if there is a question of adherence. Laboratory testing at baseline and over time should include liver biochemistries, tests of hepatic synthetic function, total blood count, indices of copper metabolism (including 24-h urinary copper excretion), and routine urinalysis for those on chelation therapy. Estimated NCC may provide the best guide to treatment efficacy but may be incalculable if either parameter is below the laboratory detection limit. Evidence of nonadherence includes clinical worsening, elevation of liver tests, and increased urinary copper excretion; hepatic deterioration may follow. Disproportionately low urinary copper excretion on chelation relative to steady state values can indicate overtreatment and is often accompanied by lower serum ceruloplasmin and serum copper and therefore lower NCC; neutropenia, anemia, and hyperferritinemia can also be present. Recently stopped chelation therapy or subtherapeutic dosages may also yield low 24-h urinary copper excretion, but typically with elevated NCC or CuEXC or increased serum copper. In patients taking zinc, adherence can be checked by measuring serum zinc or 24-h urinary zinc excretion.

---

### Wilson's disease and other neurological copper disorders [^1147L3JA]. The Lancet: Neurology (2015). Medium credibility.

The copper metabolism disorder Wilson's disease was first defined in 1912. Wilson's disease can present with hepatic and neurological deficits, including dystonia and parkinsonism. Early-onset presentations in infancy and late-onset manifestations in adults older than 70 years of age are now well recognised. Direct genetic testing for ATP7B mutations are increasingly available to confirm the clinical diagnosis of Wilson's disease, and results from biochemical and genetic prevalence studies suggest that Wilson's disease might be much more common than previously estimated. Early diagnosis of Wilson's disease is crucial to ensure that patients can be started on adequate treatment, but uncertainty remains about the best possible choice of medication. Furthermore, Wilson's disease needs to be differentiated from other conditions that also present clinically with hepatolenticular degeneration or share biochemical abnormalities with Wilson's disease, such as reduced serum ceruloplasmin concentrations. Disordered copper metabolism is also associated with other neurological conditions, including a subtype of axonal neuropathy due to ATP7A mutations and the late-onset neurodegenerative disorders Alzheimer's disease and Parkinson's disease.

---

### Liver imaging findings of Wilson's disease [^112wF7E4]. European Journal of Radiology (2007). Low credibility.

Wilson's disease is a rare, autosomal-recessive inherited disorder of copper metabolism resulting in accumulation of copper in liver. The form of liver disease varies, depending on the severity of the disease at the time of diagnosis and pathological findings include fatty changes, acute hepatitis, chronic active hepatitis, cirrhosis and occasionally fulminant hepatic necrosis. Liver imaging findings reflect a wide range of physiopathological processes of the disease and also demonstrate the associated findings of cirrhosis in cases with advanced disease.

---

### Empirical evidence for biometal dysregulation in Parkinson's disease from a systematic review and bradford hill analysis [^115Nqb9P]. NPJ Parkinson's Disease (2022). Medium credibility.

Application of the Bradford Hill model of causation to published evidence of iron dysregulation strongly supports the hypothesis that this pathology plays a causal role in nigral neurodegeneration in Parkinson's disease. More limited data is available for copper, but the available evidence cautiously supports an etiological role for this biometal in this disorder. Iron and copper are involved in a range of accepted degenerative pathways in Parkinson's disease; it is feasible therefore that therapeutic modulation of either, or both, biometals may elicit widespread mechanisms of action with potential benefits for slowing disease progression.

---

### Cross-sectional study of workers employed at a copper smelter-effects of long-term exposures to copper on lung function and chronic inflammation [^115oUGPu]. Journal of Occupational and Environmental Medicine (2022). Medium credibility.

It is important to note that this study was not able to identify potential acute effects of copper-containing dust exposure as two-thirds of the copper-exposed group (and the entire subgroup participating in the sputum biomarker assessment) used RPE during their shift on the day of sampling. By comparing the "RPE" and "non-RPE" groups for the blood biomarkers and FeNO, this limitation was partly diminished, although the sample size of the "non-RPE" group was relatively small. Nevertheless, near-term exposure (or reduction of exposure due to RPE use) would not be expected to affect the results of the chronic pathologies resulting in changes to lung function. Similarly, when inflammation is chronic in nature (ie, nonresolving), elevated levels of serum biomarkers such as IL-6, CRP, and IL-8 would be expected as noted in chronic inflammatory diseases such as chronic obstructive pulmonary diseaseand cardiovascular disease. Furthermore, CC16 is a lung-derived biomarker, secreted by epithelial cells found predominantly in the respiratory bronchioles, as well the large and small airways. It serves as a specific marker for epithelial cell dysfunction, and serum levels rise following acute exposure to inflammatory stimulus such as cigarette smoke and lipopolysaccharide. However, it is also an ideal candidate for use in longitudinal studies for lung disease of the lower respiratory tract. This is because, over time, inflammation-related damage to these epithelial cells and remodeling leads to a reduction CC16 secretion and subsequent lower serum levels than in healthy controls. As such, copper-induced effects may be characterized by elevation in CC16 levels after acute exposure (acute inflammation), whereas the more chronic effects of copper-containing dust exposure such as epithelial dysfunction would be characterized by a reduction in CC16 serum levels. Neither response was observed in this study.

---

### Association between the index of nutritional quality and lipid profile in adult women [^1122joZ8]. Endocrinology, Diabetes & Metabolism (2022). Medium credibility.

1 INTRODUCTION

Dyslipidaemia is a group of abnormalities that predispose people to heart disease by increasing the serum level of total cholesterol (TC) and low‐density lipoprotein cholesterol (LDL) and decreasing high‐density lipoprotein cholesterol (HDL). Dyslipidaemia is determined by TC, LDL, triglyceride (TG) and apolipoprotein B levels higher than the 90th percentile and/or HDL and apolipoprotein A1 levels below the 10th percentile of public people. The prevalence of dyslipidaemia is considerable in Iran, and hypertriglyceridemia was reported to be more prevalent in men whereas hypercholesterolemia, high LDL and low HDL were more prevalent in women. The American and European Cardiovascular Association recommends screening of all age groups to prevent the initial outbreak of cardiovascular disease. All new guidelines emphasize on early detection of risk factors of CVDs such as imbalanced lipid profile and high blood pressure.

Lifestyle risk factors including unhealthy diet, smoking, physical inactivity and obesity have a direct association with dyslipidaemia. For example, some diets, such as the Mediterranean diet or diets, that increase the gut‐friendly microbiota have positive effects on dyslipidemia. High levels of vitamin D in pregnancy were reported to improve lipid profile. Also, a study reported that higher blood levels of iron and copper are both associated with lower risks of lipid metabolism disorders and hyperlipidaemia. Furthermore, they are also associated with lower blood levels of total cholesterol and LDL cholesterol. As an essential trace, copper is a part of antioxidant enzymes and have protective effect on dyslipidaemias. While some studies reported that serum copper was positively associated with TC and LDL cholesterol, thereby increasing the risk of dyslipidaemia. In addition, there is evidence that high intake of some vitamins and minerals such as niacin, vitamin D, E, C and selenium play a protective role in the prevention of hyperlipidaemia. However, recent study reported vitamin C supplementation had no significant effect on serum cholesterol, triglycerides and HDL.

---

### Age-associated changes of brain copper, iron, and zinc in Alzheimer's disease and dementia with lewy bodies [^113nCwHv]. Journal of Alzheimer's Disease (2014). Low credibility.

Disease-, age-, and gender-associated changes in brain copper, iron, and zinc were assessed in postmortem neocortical tissue (Brodmann area 7) from patients with moderate Alzheimer's disease (AD) (n = 14), severe AD (n = 28), dementia with Lewy bodies (n = 15), and normal age-matched control subjects (n = 26). Copper was lower (20%; p < 0.001) and iron higher (10–16%; p < 0.001) in severe AD compared with controls. Intriguingly significant Group*Age interactions were observed for both copper and iron, suggesting gradual age-associated decline of these metals in healthy non-cognitively impaired individuals. Zinc was unaffected in any disease pathologies and no age-associated changes were apparent. Age-associated changes in brain elements warrant further investigation.

---

### Insights into trace metal metabolism in health and disease from PET: "PET metallomics" [^113vAshG]. Journal of Nuclear Medicine (2018). Low credibility.

Essential trace metals are important in many cellular and physiologic processes, including ubiquitous enzymatic reactions and protein folding. For example, copper-dependent enzymes include cytochrome-c oxidase, superoxide dismutase, and ceruloplasmin, which participate in aerobic respiration, antioxidant defense, and hepatic iron release, respectively, all of which depend on the redox activity of copper as it cycles between its 2 principal oxidation states, Cu(I) and Cu(II). Zinc is essential for the catalytic function and structure of many proteins with roles in, inter alia, metabolism, gene regulation, chromatin structure, and neurotransmission. Iron is essential in hemoglobin, respiration, and DNA and RNA synthesis, whereas manganese is important to enzymes that destroy reactive oxygen species and produce urea and nitric oxide. In healthy states, metal homeostasis is tightly controlled, and its deregulation is implicated as cause or consequence of many human diseases. Mutations in copper transporters ATP7B and ATP7A result in, respectively, Wilson's disease (WD) (characterized by copper overload) and Menkes disease (characterized by systemic copper deficiency and fatal in childhood). Copper imbalance is implicated in neurodegeneration and cancer, although whether as cause or consequence is unclear. Abnormal zinc levels occur in diabetes and cystic fibrosis, and both zinc and copper accumulate in amyloid plaques in Alzheimer disease. The study of trace metals in biology and medicine, historically known as inorganic biochemistry or bioinorganic chemistry, is growing in importance, becoming fashionably known as "metallomics".

---

### A multidisciplinary approach to the diagnosis and management of Wilson disease: executive summary of the 2022 practice guidance on Wilson disease from the American Association for the Study of Liver Diseases [^113AudPD]. Hepatology (2023). High credibility.

Regarding diagnostic investigations for Wilson's disease, more specifically with respect to serum ceruloplasmin and urinary copper excretion, AASLD 2022 guidelines recommend to recognize that basal 24-hour urinary excretion of copper in WD is typically > 100 mcg/24 hours in symptomatic patients, but a lower reference value of > 40 mcg/24 hours may indicate WD in asymptomatic patients or pediatric patients, and therefore requires clinical correlation and further investigation.

---

### Copper levels in cholestatic infants on parenteral nutrition [^113MmKLP]. JPEN: Journal of Parenteral and Enteral Nutrition (2013). Low credibility.

Background

Copper levels are primarily regulated by biliary excretion. In cholestatic patients, there is a concern that the standard dose of copper in parenteral nutrition (PN) will result in excessive copper levels. This study looked retrospectively at cholestatic infants receiving PN with measured copper levels to ascertain if this is an actual clinical concern.

Methods

All infants from the previous 10 years receiving PN who had a copper level checked and were cholestatic were reviewed. Children with metabolic or liver structural anomalies were excluded from the review. Of the 28 patients found, 26 had gastrointestinal disorders, and 82% of these infants were on the standard PN copper dose (20 µg/kg/d).

Results

Only one elevated copper level was found in a child with congenital heart disease, but 13 low levels were found. A smaller number of follow-up copper levels demonstrated that despite cholestasis, some patients require copper supplementation above standard recommendations.

Conclusion

Cholestasis does not appear to impair copper excretion enough to result in elevated levels. In fact, infants with gastrointestinal disorders may require higher than standard dosing. Monitoring copper levels appears to be necessary to appropriately regulate copper dosing for cholestatic infants receiving PN.

---

### Prion protein promotes copper toxicity in Wilson disease [^1144uaua]. Nature Communications (2025). High credibility.

Copper (Cu) is a vitally important micronutrient, whose balance between essential and toxic levels requires a tightly regulated network of proteins. Dysfunction in key components of this network leads to the disruption of Cu homeostasis, resulting in fatal disorders such as Wilson disease, which is caused by mutations in the hepatic Cu efflux transporter ATP7B. Unfortunately, the molecular targets for normalizing Cu homeostasis in Wilson disease remain poorly understood. Here, using genome-wide screening, we identified the cellular prion protein (PrP) as an important mediator of Cu toxicity in WD. Loss of ATP7B stimulates hepatic expression of PrP, which promotes endocytic Cu uptake, leading to toxic Cu overload. Suppression of PrP significantly reduces Cu toxicity in cell and animal models of Wilson disease. These findings highlight the critical regulatory role of PrP in copper metabolism and open new avenues for exploring the therapeutic potential of PrP suppression in Wilson disease.

---

### A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 practice guidance on Wilson disease from the American Association for the Study of Liver Diseases [^116atJJG]. Hepatology (2025). High credibility.

Wilson disease — household water and cookware precautions — copper content of drinking water can vary from < 0.005 mg/L to as high as 30 mg/L, and a water copper content > 100 μg/L is considered elevated for WD; water treatment to decrease the copper concentration is indicated. Residents with WD should be encouraged to flush tap water for cooking or drinking after allowing it to run for at least half a minute or until cool, and home water filtration systems may be equipped with carbon-based filters or utilize reverse osmosis for metal removal, with carbon-based home water filters able to decrease copper content if changed at recommended intervals. Unlined copper or bronze cookware can leach copper into foods, so unlined copper mixing bowls and drinking mugs should be avoided by patients with WD, whereas lined copper pots and pans are described as safe to use.

---

### Prion protein promotes copper toxicity in Wilson disease [^112YWHpA]. Nature Communications (2025). High credibility.

Our data also suggest that PrP has to be considered in the broader context of Cu metabolism and Cu-related disorders. On one hand, higher expression of PrP might help to satisfy a metabolic demand for extra copper in cells or tissues with elevated Cu consumption. On the other hand, high PrP expression could promote abnormal accumulation of Cu, which fuels numerous processes favoring malignant transformation of cells and tissues. In agreement with this, we observed the highest expression of PrP in cholangiocarcinoma nodes in the liver of Atp7b −/− mice, whereas PrP depletion almost completely prevented tumor growth. High PrP expression has been also reported as an unfavorable factor for overall survival of patients with hepatocellular carcinoma. Thus, a growing body of evidence indicates that PrP is tightly integrated in the mechanisms regulating Cu transport and distribution in health and disease. It may be worth exploring the role of PrP in other genetic disorders causing alterations in Cu metabolisms (such as MEDNIK syndrome or AP1B1 deficiency) and in cancer. A number of PrP suppression strategies are being explored for the therapy of prion disease. Our data indicating that PrP plays a role in mediating copper toxicity in WD warrant future studies to evaluate the therapeutic potential of PrP suppression in this and other disorders of copper metabolism.

---

### Cu-bis (thioureido) complex: a potential radiotracer for detecting oxidative stress and neuroinflammation in neurodegenerative diseases [^111Lsmwc]. Seminars in Nuclear Medicine (2025). Medium credibility.

Neurodegenerative diseases, characterized by progressive neuronal degeneration and associated with neuroinflammation and oxidative stress, present significant challenges in diagnosis and treatment. This review explores the potential of copper(II)-bis(thiosemicarbazone) complexes, particularly Cu-ATSM, as a dual-purpose radiopharmaceutical for imaging and therapeutic interventions. Cu-ATSM exhibits unique redox-dependent retention in pathological microenvironments, driven by mitochondrial dysfunction and hyper-reductive states, which enables the noninvasive detection of oxidative stress via positron emission tomography (PET). Preclinical studies demonstrate its efficacy in mitigating neuroinflammation by suppressing glial activation, reducing the secretion of pro-inflammatory cytokines (e.g. TNF-α, MCP-1), and increasing the expression of neuroprotective metallothionein-1 (MT1). Some Clinical research reveals elevated ⁶⁴Cu-ATSM uptake in Parkinson's disease (PD), Alzheimer's disease (AD), and amyotrophic lateral sclerosis (ALS) patients, correlating with disease severity and regional oxidative stress markers. Furthermore, Cu-ATSM derivatives show promise in modulating blood-brain barrier (BBB) permeability, enhancing amyloid-β clearance, and restoring copper homeostasis in ALS models. Despite these advances, limitations such as small cohort sizes and heterogeneity in clinical studies underscore the need for larger-scale validation. Multimodal imaging integrating PET and MRI, alongside novel structural analogs targeting Aβ plaques and redox imbalances, emerges as a strategic direction for future research. Collectively, Cu-ATSM represents a transformative tool for elucidating neuropathological mechanisms and advancing therapeutic strategies in neurodegenerative disorders.

---

### Connecting copper and cancer: from transition metal signalling to metalloplasia [^112okvuS]. Nature Reviews: Cancer (2022). High credibility.

Copper is an essential nutrient whose redox properties make it both beneficial and toxic to the cell. Recent progress in studying transition metal signalling has forged new links between researchers of different disciplines that can help translate basic research in the chemistry and biology of copper into clinical therapies and diagnostics to exploit copper-dependent disease vulnerabilities. This concept is particularly relevant in cancer, as tumour growth and metastasis have a heightened requirement for this metal nutrient. Indeed, the traditional view of copper as solely an active site metabolic cofactor has been challenged by emerging evidence that copper is also a dynamic signalling metal and metalloallosteric regulator, such as for copper-dependent phosphodiesterase 3B (PDE3B) in lipolysis, mitogen-activated protein kinase kinase 1 (MEK1) and MEK2 in cell growth and proliferation and the kinases ULK1 and ULK2 in autophagy. In this Perspective, we summarize our current understanding of the connection between copper and cancer and explore how challenges in the field could be addressed by using the framework of cuproplasia, which is defined as regulated copper-dependent cell proliferation and is a representative example of a broad range of metalloplasias. Cuproplasia is linked to a diverse array of cellular processes, including mitochondrial respiration, antioxidant defence, redox signalling, kinase signalling, autophagy and protein quality control. Identifying and characterizing new modes of copper-dependent signalling offers translational opportunities that leverage disease vulnerabilities to this metal nutrient.

---

### Inherited metabolic disease of the liver [^113JsKvH]. Current Opinion in Gastroenterology (2008). Low credibility.

Purpose Of Review

Elucidation of metabolic pathways for copper and iron improved our understanding of Wilson disease and genetic hemochromatosis. Some inherited liver diseases are now characterized by protein-folding mutations, including Gaucher disease, cystic fibrosis and ZZ alpha1-antitrypsin deficiency. Studies now focus on associations between glycogen storage disease, hepatic adenoma formation and transformation to hepatocellular carcinoma. Continued progress in the study of the diagnosis, natural history and treatment of inherited liver diseases is the subject of this review.

Recent Findings

Further understanding of metabolic pathways for iron and copper have led to a search for factors that modify phenotypic expression of Wilson disease and genetic hemochromatosis. Hepcidin plays a key role in modulating iron uptake in iron-overload disorders and new studies elucidate hepcidin regulation. For glycogen storage diseases, studies on the natural history and hepatocellular transformation necessitate tumor surveillance and possible early transplantation. A better understanding of genetic and nongenetic modifiers in ZZ alpha1-antitrypsin deficiency and other disorders of protein misfolding will improve our ability to manage these patients.

Summary

Recent discoveries in iron, copper and glycogen metabolism advance our ability to diagnose and treat inherited metabolic diseases of the liver. Some of these important findings are detailed in this review.

---

### Designing clinical trials in Wilson's disease [^117P2ggb]. Hepatology (2021). Medium credibility.

Study Population

Clinical Presentation

The clinical phenotype of WD patients at presentation is variable and includes acute and chronic symptoms (Fig. 1). Given that nonacute phenotypes are not clearly separated, studies should include all phenotypes except those with acute liver failure (ALF) or end‐stage disease refractory to medical therapy (see Exclusion Criteria below).

FIG. 1
Clinical course of WD. After a subclinical period, WD presents with hepatic (mean age, 17.6 years) and/or neurological (mean age, 23.4 years) symptoms. Approximately 60% have both. Three percent to 5% present with acute hepatic failure (ALF), which is fatal without liver transplantation. In the remaining patients, the medical treatment aims at preventing or stopping disease progression and, if possible, inducing a regression of symptoms.

Clinically asymptomatic siblings of WD patients are effectively identified by genetic testing. Though appearing healthy, affected persons have elevated hepatic copper and progress to overt disease without treatment. They can be included in clinical trials after clinical and metabolic characterization.

As preconception, prenatal, and newborn genetic testing becomes more widespread, fetuses and newborn infants will be diagnosed before development of pathological copper overload. Treatment will aim to prevent development of injury and disease. Drug selection and age for treatment initiation is unclear and require further study.

Given that disease course and underlying pathophysiology is similar, children ≥ 12 years old and adults can be included in the same RCTs after appropriate bioethical considerations and dosing modification. Separate studies are needed for younger children.

Patient Genotype

Only approximately half of reported ATP7B mutations are considered pathogenic or likely pathogenic. Several studies failed to demonstrate clear genotype‐phenotype correlations. Siblings and even monozygotic twins may have diverse phenotypes. Thus, stratification based on genotype is not reasonable, except in future trials for gene repair.

---

### A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 practice guidance on Wilson disease from the American Association for the Study of Liver Diseases [^114AkHwB]. Hepatology (2025). High credibility.

Wilson disease — treatment targets and copper monitoring during chelation are defined by urinary copper metrics: Adequacy of treatment is judged by clinical and biochemical improvement and subsequent stability and by measuring 24 h urinary copper excretion on treatment. Urinary copper excretion upon initiation of treatment is often > 1000 µg/24 h and decreases over time on treatment to approximately 3–10 times the upper limit of normal for urinary copper excretion (typically approximately 150–500 µg/24 h). Generally, with nonadherence to therapy over time, urinary copper rises. Values of urinary copper excretion < 100 µg/24 h may indicate some degree of copper deficiency due to overtreatment, in which case serum copper is expected to be lower than pretreatment values, reversible sideroblastic anemia and neutropenia may be present, and overtreatment can result in hepatic iron overload. In contrast, when urinary copper excretion accompanies nonadherence, serum copper increases, reflecting increased NCC.

---

### A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 practice guidance on Wilson disease from the American Association for the Study of Liver Diseases [^116JatVc]. Hepatology (2025). High credibility.

American Association for the Study of Liver Diseases guidance statements 19–20 — patients with WD should avoid intake of foods and water containing high concentrations of copper, especially during the first year of treatment, and supervision by a registered dietitian (RD) may help to avoid overly restrictive meal patterns or undue anxiety about diet. Patients with WD unable to maintain adequate nutritional intake require dietary management that includes supplements formulated to meet dietary needs while avoiding excess copper intake, and arranging for participation by a knowledgeable RD may be helpful.

---

### Inherited metabolic liver disease [^111WCynf]. Current Opinion in Gastroenterology (2005). Low credibility.

Purpose Of Review

The purpose of this review is to identify and discuss recent findings related to inherited metabolic disorders of the liver that increase our understanding of the pathophysiology and treatment for hemochromatosis and other iron overload disorders, Wilson disease and alpha one antitrypsin deficiency.

Recent Findings

The main theme in the recent discoveries for both iron overload disorders and Wilson disease is our increasing understanding that the phenotypic expression of these disorders are greatly influenced by genes involved in the metabolic pathways for these metals, or influence the progression of liver disease independent of metal metabolism. For example, the role of hepcidin dysregulation in hemochromatosis has been a surprising discovery that provides some mechanistic understanding for the increased iron absorption that is present in this disorder.

Summary

Given the recent explosion of information on iron and copper metabolism and the cellular processing of alpha one antitrypsin, the highlights reviewed in this article will help the reader keep up to date with the current understanding of these diseases and potential future approaches to their treatment.

---

### A role for low hepatic copper concentrations in nonalcoholic fatty liver disease [^111UW1mJ]. The American Journal of Gastroenterology (2010). Low credibility.

Objectives

Copper has a role in antioxidant defense, lipid peroxidation, and mitochondrial function, and copper deficiency has been linked to atherogenic dyslipidemia. We aimed to investigate the potential role of copper availability in the pathogenesis of nonalcoholic fatty liver disease (NAFLD).

Methods

Patients with NAFLD (n = 124) were compared to patients with chronic hepatitis C (n = 50), hemochromatosis (5), alcoholic liver disease (3), autoimmune hepatitis (1), and control subjects (7). We determined liver and serum copper concentrations with correlation to clinical, histological, and biochemical parameters in humans. The effect of dietary copper restriction on liver histology and intermediary metabolism in rats was investigated.

Results

Hepatic copper concentrations in patients with NAFLD were lower than in control subjects (17.9 ± 8.4 vs. 31.4 ± 8.2 microg/g; P < 0.001) and in patients with other liver diseases (P < 0.05 for all liver diseases). In patients with NAFLD, lower liver copper was correlated with more pronounced hepatic steatosis (0.248; .010), fasting glucose (0.245; .008), and components of the metabolic syndrome (MetS; .363; P < 0.001). Patients with nonalcoholic steatohepatitis (NASH; 1) had lower hepatic copper concentrations than those with simple steatosis (3; .038). Restriction of dietary copper in rats induced hepatic steatosis and insulin resistance (IR).

Conclusions

Reduced hepatic copper concentrations are found in human NAFLD and are associated with more pronounced hepatic steatosis, NASH, and components of the MetS. The development of hepatic steatosis and IR in response to dietary copper restriction in rats suggests that copper availability may be involved in the development of NAFLD.

---

### A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 practice guidance on Wilson disease from the American Association for the Study of Liver Diseases [^112Bnqzp]. Hepatology (2025). High credibility.

Wilson disease (WD) — pathophysiology and epidemiology — is defined by impaired ATP7B-mediated copper handling in hepatocytes where absent or impaired function decreases biliary excretion causing toxic hepatic copper accumulation and, when storage is exceeded, copper deposits in extrahepatic organs including the brain, kidneys, and cornea; loss of ATP7B also diminishes incorporation of copper into ceruloplasmin leading to low circulating ceruloplasmin. Dietary context notes that the average diet contains 2–5 mg/day of copper and the recommended intake is 0.9 mg/day. WD occurs worldwide with prevalence estimated at approximately 30 per million population.